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ABSTRACT
Glioblastoma is the most malignant brain cancer. Currently no cure has been established.
The lethality of glioblastoma is a consequence of its extremely invasive nature: it rarely
metastasizes outside the nervous system but effectively spreads throughout the brain
parenchyma. This property, in addition to its challenging location makes it impossible to
remove surgically. Furthermore, the tumors are heterogeneous and contain cells that are
resistant to radiation therapy as well as to the only currently approved chemotherapy,
temozolomide.
Netrins are secreted extracellular matrix proteins. They were initially identified as proteins
essential for the correct axonal wiring of both vertebrates and invertebrates. Later, they
were observed to regulate the branching morphogenesis of various organs including
mammary gland, lungs and pancreas. During recent years increasing number of studies have
linked netrins to various forms of cancer.  For example, netrin-1 induces the invasion of
pancreatic, colorectal and hepatocytic cancers and medulloblastoma and promotes the
survival of breast and lung cancer and neuroblastoma. Netrin-4 can modulate tumor growth,
angiogenesis, and metastasis.
In the current work, we analyzed how netrins contribute to glioblastoma growth. We
discovered that both netrin-1 and -4 contribute to the malignancy of glioblastoma via
independent pathways. Netrin-1 was upregulated in glioblastoma whereas netrin-4 was
downregulated. However, both were associated with poor patient prognosis. The signaling
pathways mediating the effects of these proteins were systematically explored.
First, our results revealed a new mechanism where netrin-4 controls glioma cell proliferation
via UNC5B and ITGB4 receptors. During normal cell culture conditions netrin-4 is abundantly
expressed, and it binds to both UNC5B and ITGB4 receptors that counteract each other and
keep glioma cell proliferation in balance. However, during glioma progression netrin-4
expression is decreased and the signaling is shifted towards ITGB4. This led to increased cell
proliferation and tumor growth.
Second, we discovered a mechanism through which netrin-1 promotes cell invasion. Netrin-
1 expression associated with astrocytomas which are invasive glioma subtype. In
glioblastoma cells it interacted with Notch2 and Jagged1 and facilitated the activation of the
signaling. Subsequently, this led to an increase in cell invasion in vitro and in vivo.
Furthermore, a unique invasion pattern was characterized where netrin-1 expressing cells
were promoting the motility and stemness of the invasion leading stem-like cells.
Third, we designed and engineered a recombinant peptide that had the capacity to inhibit
netrin-1 signaling. This peptide was able to overcome the effects of the full-length netrin-1
and specifically inhibited the invasiveness of the stem-like glioblastoma cells in vitro and in
vivo. This peptide may prove out to be of therapeutic value in GBM treatment.
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TIIVISTELMÄ
Glioomat ovat glia- eli hermotukisoluista alkunsa saavia aivokasvaimia. Glioblastooma on
näistä syöpäkasvaimista pahanlaatuisin. Siihen ei toistaiseksi ole kehitetty hoitoa, ja
potilaiden keskimääräinen elinaika on 15 kuukautta diagnosoinnin jälkeen. Glioblastooman
pahanlaatuisuus johtuu kasvaimen syöpäsolujen aggressiivisesta leviämisestä terveen
aivokudoksen sekaan. Tästä syystä se on lähes mahdoton poistaa kirurgisesti. Nämä
syöpäsolut ovat myös sädehoidolle sekä toistaiseksi ainoalle hyväksytylle lääkehoidolle,
temozolomidille, vastustuskykyisiä
Netriinit ovat erittyviä soluväliaineen proteiineja. Niiden on alun perin havaittu säätelevän
aksonien kehitystä yksilönkehityksen aikana sekä selkärankaisissa että selkärangattomissa.
Myöhemmin niiden on osoitettu säätelevän myös muiden haaroittuneiden elinten
muodostumista. Viime vuosien aikana yhä useammat tutkimukset ovat osoittaneet
netriinien olevan tärkeässä osassa myös syöpäbiologiassa: netriini-1 lisää useiden eri
syöpätyyppien leviämistä sekä syöpäsolujen selviytymistä, ja netriini-4 puolestaan on
yhdistetty syöpäkasvainten kykyyn kasvattaa verisuonia sekä niiden kykyyn lähettää
etäpesäkkeitä.
Tässä väitöskirjatyössä on tutkittu netriinien vaikutuksia glioblastoomaan. Tutkimuksissa
osoitettiin, että lisääntynyt netriini-1:n tuotto ja vastakohtaisesti vähentynyt netriini-4:n
tuotto ovat yhteydessä potilaiden huonompaan ennusteeseen. Signalointireittejä, joiden
kautta nämä proteiinit vaikuttavat syöpäsoluihin, seulottiin systemaattisesti. Tutkimuksessa
havaittiin, että kumpikin näistä proteiineista vaikuttaa glioblastoomasoluihin itsenäisesti eri
signaloittireittien välityksellä. Netriini-4:n osoitettiin olevan tärkeä glioblastoomasolujen
jakautumisen säätelijä ja sen tuoton vähentyminen mahdollisti kontrolloimattoman solujen
jakautumisen ja täten kasvaimen kasvun. Netriini-1:n puolestaan osoitettiin olevan
merkittävä glioblastoomasolujen liikkuvuuden säätelijä. Sen lisääntynyt tuotto sai aikaan
syöpäsolujen muuttumisen kantasolumaisemmiksi ja aggressiivisemmin terveen
aivokudoksen sekaan leviäviksi.
Lisäksi tässä työssä suunniteltiin ja rakennettiin peptidi, joka pystyi estämään netriini-1:n
vaikutukset glioblastoomasoluissa. Koska tämän peptidin tuotto vähensi
glioblastoomasolujen kantasolumaisuutta sekä niiden kykyä levitä terveen aivokudoksen
sekaan, voi sillä tulevaisuudessa olla potentiaalia glioblastooman lääkehoidon kehityksessä.
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INTRODUCTION
Central nervous system (CNS) consists of two types of cells: neurons and glial cells.  While
neurons are the main cells that process and mediate information the glial cells provide many
supportive functions to them. Glial cells can be further divided into macro- and microglial
cells (reviewed in Sierra et al., 2016). Microglial cells are specialized immune cells of the CNS
(Gehrmann et al., 1995). They are a special group of macrophages that are responsible for
the immune defense of the CNS. Within the human brain, three types of macroglial cells are
present: astrocytes, oligodendrocytes and ependymal cells. The main function of
oligodendrocytes is to isolate the neurons: they wrap around the neurons and provide
isolating myelin sheath for them (Baumann and Pham-Dinh, 2001). Astrocytes are branched
cells which are in contact with neurons, each other and blood vessels (Nag, 2011). They
provide many supporting functions for neurons for example by up taking excess potassium
ions that are produced during synaptic emission or by secreting many growth factors that
are essential for the well-being of neurons (Krencik et  al.,  2016).  In  addition,  astrocytes
participate in the development of blood brain barrier (Haseloff et al., 2005). Ependymal cells
are specialized cells that create the linings of the ventricles of the brain and the central canal
of the spinal cord. Furthermore, they contribute to the production of cerebrospinal fluid.
Diffuse gliomas are tumors of macroglial cells within the brain. They are the most common
primary brain tumors in humans (Maher et al., 2001; Ostrom et al., 2015). Approximately
400 gliomas are diagnosed in Finland per year (Maenpaa, 2010). Currently the cell of origin
of gliomas is unknown but it has been proposed that the tumors arise from mutated mature
astrocyte or oligodendrocyte or undifferentiated neural stem or precursor cell. Gliomas are
graded into four grades on the basis of their malignancy. Most aggressive form of these
tumors, glioblastoma is a devastating disease which has remained incurable despite
numerous treatment attempts during recent years. The lifetime expectancy of patients is
only 15 months after diagnosis. The lethality of glioblastoma is a result of its highly
heterogenous and infiltrative phenotype (Maher  et al., 2001). The tumors are impossible to
remove surgically because of aggressively, throughout the brain invading tumor cells. In
addition, the glioblastoma cells are extremely resistant to radiation and chemotherapy
(Raizer and Parsa, 2015). Therefore, better understanding of the biology of the glioblastoma
cells is needed in hopes of invention of new therapeutic options.
Netrins are secreted proteins that are essential for the development of both vertebrates and
invertebrates. They act as chemoattractants and regulate both cell polarization and
migration during axon guidance, vascular patterning and branching morphogenesis of
different organs (Cirulli and Yebra, 2007). Within recent years netrins have also been linked
to tumorigenesis of various epithelial and nervous system cancers including neuroblastoma,
colorectal, breast and lung cancer (Ko  et al., 2014). They have been shown to regulate cancer
cell migration and survival.
In this thesis the role of netrins in human glioblastoma tumors was assessed. The role of both
netrin-1 and netrin-4 was investigated in different aspects of glioma biology, including cancer
cell proliferation, survival, invasion and stemness. In addition, the signaling pathways
mediating the effects of netrins were screened systematically. The findings help us to better
understand the molecular mechanisms behind the disease and guide our way to the
development of new treatment options.
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REVIEW OF THE LITERATURE
1. Human gliomas 
1.1. Classification of gliomas 
Gliomas  are  the  most  common  human  primary  brain  tumors.  They  are  tumors  of  the
macroglial cells, mainly astrocytes and oligodendrocytes. Gliomas often emerge in the
frontal lobe area and are slightly more common in men than in women (Cancer Genome
Atlas Research Network et  al., 2015). The classification of gliomas has been based on
histological characterization of the tumors according to the guidelines set by the World
Health Organization (WHO) (Louis et  al.,  2007).  Until  this  year  gliomas  were  divided  into
three major classes: astrocytoma, oligoastrocytoma and oligodendroglioma, based solely on
their histopathological status of glial cell differentiation (Louis et  al., 2007; Maher et  al.,
2001). According to this classification astrocytomas were divided into grade II-IV tumors
whereas oligoastrocytoma and oligodendrogliomas were typically grade II tumors.
Within recent years, excessive efforts have been made to investigate the genetic alterations
of gliomas. These advances have revealed distinct mutations in different glioma subtypes.
Based on these findings WHO has published new guidelines for the treatment and
classification of these tumors (Louis et  al.,  2016).  According  to  the  current  view  gliomas
emerge from a common precursor cell. Therefore previous glioma classes, astrocytomas,
oligoastrocytomas and oligodendrogliomas have been combined under one group named
diffuse gliomas. This major group is then further divided into subgroups based on the
different mutations acquired by the tumors (figure 1). Previous oligoastrocytoma class has
been completely excluded from the new classification since these tumors can now be
included into the new subtypes based on the mutational status. This simplifies the
classification of oligoastrocytic tumors that present characteristics of both astrocytomas and
olidendrogliomas on the cellular level.
According to the current view, mutation in isocitrate dehydrogenase (IDH) gene is the
earliest mutation on the progression of gliomas (Balss et al., 2008; Sanson et al., 2009). This
mutation  is  observed  in  80%  of  the  low  grade  diffuse  gliomas  and  it  is  common  in  both
astrocytic and oligodendrocytic tumors. The mutation occurs more frequently in IDH1 gene
but also mutations in IDH2 gene have been detected. If additional co-deletion of
chromosome  arms  1p  and  19q  is  detected  tumors  are  categorized  as  grade  II  or  III
oligodendrogliomas (Louis et  al., 2016). If a mutation in the tumor suppressor protein 53
(TP53) and transcription regulator ATRX (ATRX) are detected the tumors are diagnosed as
diffuse astrocytoma grade II. Furthermore, loss of chromosome arms 9p and 10q are
commonly observed in anaplastic astrocytoma grade III and secondary glioblastoma (GBM)
grade IV, respectively.
The division of the diffuse gliomas into mutational subtypes improves the diagnosis and the
prediction of patient response to treatment. The prognosis of oligodendroglioma patients is
better than astrocytoma patients with median survival times 8.0 years and 6.3 years
respectively (Cancer Genome Atlas Research Network et  al.,  2015).  The  median  age  of
patients diagnosed with grade II or III glioma is 42.6 years at the time of diagnosis and does
not significantly vary between the subtypes (Cancer Genome Atlas Research Network  et al.,
2015).
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Figure 1. Classification of human gliomas. Schematic presentation of the progression and
current classification of diffuse gliomas. White boxes depict gained mutations and grey boxes
the tumor classification. See explanation for abbreviations on page 8-9.
1.2. Glioblastoma 
Among gliomas, glioblastoma multiforme (GBM) is the most malignant tumor. They emerge
either as primary tumors without previous clinical manifestations or, as described above, as
secondary tumors that rise from a lower grade gliomas (figure 1). The majority,
approximately 90% of the GBMs are primary tumors and 10% progress from diffuse
astrocytoma within 5 years (Ohgaki and Kleihues, 2013). Secondary GBMs are often located
in the frontal lobe whereas primary GBMs have no location specificity (Lai et al., 2011). The
median age at the time of diagnosis is 45 years for secondary GBM patients and 60 years for
primary GBM patients (Ohgaki and Kleihues, 2013). The expected lifetime of patients after
diagnosis is 15 months for primary GBM and 31 months for secondary GBM (Louis  et al.,
2016).
The histology of primary and secondary GBM is similar. However, the accumulated mutations
vary from each other. Primary glioblastomas carry wildtype IDH whereas the majority of
secondary glioblastomas have mutated IDH. Since secondary GBMs have developed from the
low grade astrocytomas they also harbor mutations in the TP53 and ATRX. Primary GBMs
commonly have amplification of epidermal growth factor receptor (EGFR), mutated
phosphatase and tensin homolog (PTEN), loss of whole chromosome 10, deletion in cyclin
15
dependent kinase inhibitor 2 (CDKN2) and mutated telomerase reverse transcriptase (TERT)
promoter (Ohgaki et al., 2004).
Several other less frequent genetic aberrations have been detected in GBM tumors. Based
on these there have been attempts to divide the GBMs into 3-4 molecular subtypes (Brennan
et al., 2013; Verhaak et  al., 2010). The subtypes include classical, proneural, neural and
mesenchymal type GBM. While the majority of secondary GBMs belong to proneural
subtype, primary GBMs can belong to any of them. Classical subtype is characterized by EGFR
amplification (97%) and CDKN2 deletion, proneural with IDH and TP53 mutations and
PDGFRA amplifications, mesenchymal GBMs frequently have NF-1 mutation and MET
amplification (Phillips et al., 2013; Verhaak et al., 2010). These subtypes may be of clinical
value if personalized treatments will be available for GBM. However, the GBM tumors may
be even more heterogeneous, which may complicate the classification. When one biopsy of
GBM tumor was analyzed on single cell RNA sequencing it was revealed that individual cells
among the biopsy may belong to different tumor subtype (Patel et al., 2014). Furthermore,
the copy number alterations differ within several samples collected from various locations
around same tumor (Sottoriva et  al., 2013). Therefore, individual GBM cells display great
heterogeneity within each tumor. One biopsy taken during the operation may not necessarily
properly characterize the tumor and may lead to incorrect GBM subtype classifications.
Especially this aspect should be considered if personalized GBM treatment will be applied in
the future.
1.2.1. Hallmarks of glioblastoma 
The histopathological features of GBM tumors are infiltrative growth within the healthy brain
tissue, necrotic tumor core which is surrounded by dense cell areas called pseudopalisade
structures and excessive angiogenesis resulting in abnormal tumor vasculature called
glomerular vessels (Brat et  al., 2004a; Rojiani and Dorovini-Zis, 1996). Especially the
pseudopalisade structures and the glomerular vessels distinguish GBM tumors from the
lower grade II and III astrocytomas and oligodendrogliomas. It is suggested that hypoxia
within  the  tumor  core  is  the  cause  of  these  GBM  hallmarks.  Hypoxia  upregulates  a
multifunctional protein called hypoxia inducible factor (HIF) in the tumor cells. HIF regulates
several signaling pathways that are linked to cell metabolism, motility, angiogenesis and
stemness of the tumor cells (reviewed in (Rankin and Giaccia, 2016) ). The pseudopalisade
structures are shown to be hypoxic and to consist of actively migrating cells (Brat et  al.,
2004b). Furthermore, HIF can upregulate the production of VEGF within the tumors which
leads to excess endothelial cell proliferation. However, the vessels formed are tortuous and
leaky which results in increased interstitial pressure and cancer cell evasion from the primary
tumor (Jain, 2013). This causes a cycle where the lack of nutrients and oxygen within the
tumor core forces the tumor cells to disseminate and invade into the brain parenchyma. This
infiltrative phenotype makes it impossible for the GBM to be completely resected with
surgery.
1.2.1.1. Invasive modes of glioblastoma cells 
GBM cells use neuron networks and white matter tracts as highways to spread throughout
the brain (figure 2). In addition, they actively co-opt the brain vessels, attach to the vascular
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basement membrane and move along the perivascular space. Despite the active spreading
within the brain parenchyma, GBM cells extremely rarely metastasize to other organs.
The molecular mechanisms driving the motility of GMB cells have been widely investigated
during recent years. The major barrier that the tumor cells encounter while leaving the
primary tumor is the extracellular matrix (ECM) of the brain. It consists mainly of hyaluronic
acid, proteoglycans and tenascin glycoproteins (Novak and Kaye, 2000). Due to the lack of
laminin, fibronectin or collagens it is relatively soft matrix and less fibrous and cross-linked
than the ECM in many other organs. The vascular basement membrane that the GBM cells
also use as a migratory platform contains fibronectin, laminin and collagens III and IV.
Cells attach to the ECM via specialized adhesion receptors. The range of these receptors
overexpressed in GBM tissue include integrin receptors α3β1, α2β1, α5β1, α6β1, α6β4,
α9β1, αvβ3 and αvβ5 that bind various ECM proteins including laminin, tenascins, fibronectin
and vitronectin (Gingras et al., 1995; Paulus et al., 1993). In addition, hyaluronan receptors
CD44, ICAM-1 and L1-CAM are upregulated in GBM compared to normal brain (Gingras et
al., 1995; Paulus et  al.,  1993).  Via  these  receptors  the  GBM  cells  can  attach  to  the
surrounding matrixes and migrate away from the primary tumor site. In addition, GBM cells
express various proteases that can cleave the ECM and thereby aid the motility of the cells.
The main proteases expressed by are ADAMs, uPA, MMPs and cathepsins (Nakada et  al.,
1999; Rempel et al., 1994; Rooprai et al., 1998; Wildeboer et al., 2006; Yamamoto et al.,
1994). While the cancer cells are disseminating from the primary tumor the proteases play
an important role in detaching the invasive cells from the tumor mass.
Figure 2. GBM cell invasion. (A) Schematic presentation of GBM cells disseminating from the
primary tumor. GBM cells can either invade along (B) the border of stroma and blood vessels,
(C)  within  the  perivascular  space  of  blood  vessels  or  (D)  along  the  white  matter  tracts.
Modified from (Gritsenko et al., 2012)
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Cancer cells can invade as single cells or collectively and, the invasion mode can be amoeboid
or  mesenchymal  like  (Clark  and  Vignjevic,  2015;  Friedl  and  Wolf,  2010).  Mesenchymal
invasion is dependent on integrins and proteases while the amoeboid like invasion is
mediated by Rho/Rac signaling and actin remodeling which allows the cells to squeeze
through soft matrixes. In general, stiffer ECM is proinvasive (Kai et al., 2016). The rigidity
provides more adhesion sites to the cells and the support allows them to use mechanical
force to move forward.
The composition of the brain ECM suggests that the GBM cells utilize amoeboid type
invasion. However, the variety of adhesion receptors and proteases expressed by the GBM
cells indicates that they favor mesenchymal type invasion. Interestingly, depending on the
matrix GBM cells are capable of both invasion types in vitro (Herrera-Perez et al., 2015). GBM
cells implanted into rat brain showed more Rho/Rac activity upon invasion along the white
matter tracts than when moving within the perivascular space (Hirata et al., 2012). These
findings suggest that the GBM cells are plastic and can adjust their invasive mode according
to their surroundings. Furthermore, the GBM cells themselves modulate the surrounding
ECM. They secrete fibronectin, laminin and collagens which make the ECM stiffer and
support their invasive phenotype (Bjerkvig et al., 1989; Mahesparan et al., 2003).
Recently, it was observed that the distant, invasive GBM cells form a functional network. The
tumor cells  are  in  contact  within  each other  via  long,  actin  rich  membrane tubes  termed
tumor microtubes (TM) (Osswald et al., 2015). TMs allow the tumor cells to communicate
within each other despite the distance. For example, cells were able to send calcium signaling
waves via TMs. Furthermore, when part of the tumor was exposed to radiation and cells had
died, distant cells could use the TMs to travel to the site of damage and replace the dead
cells. Based on these findings GBM tumors are very plastic and dynamic entities.
1.2.2. Current standard care of glioblastoma 
The current treatment options of newly diagnosed and secondary glioblastoma rely heavily
on surgical resection and radiation therapy of the tumor. The surgical resection of GBM is
aimed to perform as aggressively as possible. To locate the tumor and map the functional
brain regions functional magnetic resonance imaging and computational tomography are
performed before the surgery (Raizer and Parsa, 2015). During the operation Gliolan (5-
aminolevulinic acid labeling) is administered to the patients. This fluorescent dye
accumulates into the tumor cells allowing them to be visually detected during the operation.
If the tumor is located near functional brain regions the craniotomy can be performed to
awake patients (Raizer and Parsa, 2015). This allows the careful mapping of for example
speech areas during the operation. After the surgery the patient is given concomitant
radiation and chemotherapy. Currently only one drug, temozolomide (TMZ), is approved for
the standard care of newly diagnosed glioblastoma.
However, due to the infiltrative growth the surgical resection is nearly always incomplete.
The remaining tumor cells are capable of growing a new tumor and lead to recurrent
glioblastoma for which there are no common treatment guidelines. Surgical resection and
TMZ are often utilized. In addition, several targeted therapies have been investigated within
recent years, which will be discussed below.
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1.2.2.1. Temozolomide therapy  
TMZ was discovered in 1980s (reviewed in (Friedman et al., 2000) ). Its effect is based on its
capability to alkylate DNA in different positions. The most toxic methylation occurs in the
O6-guanine position. This leads to defects in translation of DNA, subsequent cell cycle arrest
and apoptotic death of the cancer cells. TMZ has been shown to effectively kill glioblastoma
cells in mice xenograft studies (Friedman et  al., 1995; Plowman et  al., 1994). In phase III
clinical trial (EORTC-NCIC trial) containing 573 high-grade glioma patients concomitant
radiation and TMZ treatment after first surgery prolonged median patient survival from 12,1
months to 14,6 months (Stupp et  al.,  2005).  However,  the  treatment  did  not  cure  the
patients but offered only prolonged survival. Within a five years follow-up time most of the
patient had had a recurrent tumor and died of the disease (Stupp et al., 2009). The major
side-effects of TMZ treatment were grade 3 or 4 hematologic toxic effects which were
observed in seven percent of patients (Stupp et al., 2005).
In approximately 55% of the glioma patients TMZ treatment showed no effect. This is due to
active O6-methylguanine-DNA methyltransferase (MGMT) enzyme in the tumor cells. MGMT
is an excision repair enzyme which removes the TMZ induced O6-guanine methylation and
thereby prevents the TMZ induced cell death. However, in some patients the MGMT enzyme
is not expressed because of epigenetic silencing of the MGMT promoter regions. This patient
group responds well to TMZ treatment (Stupp et al., 2005). The genetic testing for the MGMT
status of the patients allows the targeting of the treatment. This is important especially for
the elderly patients. However, the MGMT status may have potential prognostic value only
among the patients with classical GBM subtype (Brennan et al., 2013).
1.2.2.2. Targeted therapies 
Because of the large number of patients that do not respond to TMZ therapy, new
therapeutic applications are needed. One of the hallmarks of glioblastoma is excessive
angiogenesis in the tumors. Therefore, anti-angiogenic therapy is a possible therapeutic
option for glioblastoma. Bevacizumab is an antibody which neutralizes the vascular
endothelial growth factor A and thus inhibits the signaling through vascular endothelial
growth factor receptor (Presta et al., 1997). This reduces the angiogenesis in the tumors and
thereby limits tumor’s oxygen supply and growth. Bevacizumab has been effective in animal
models of several cancers including glioblastoma (Ferrara et al., 2004; Jahnke et al., 2009;
Mathieu et al., 2008) . In addition, it has been proven effective in two phase I clinical trials
that included patients with advanced solid tumors including colon, renal, lung, breast and
cervical cancer (Gordon et al., 2001; Margolin et al., 2001).
Because of the promising treatment results in other cancers it was considered for
glioblastoma therapy too. So far several phase II trials administering bevacizumab with TMZ
or other therapeutics to patients with recurrent GBM have been conducted (reviewed in
(Field et al., 2015; Niyazi et al., 2016; Seystahl et al., 2016; Venur et al., 2015) ). Majority of
the studies administered bevacizumab in combination with irinotecan. A slight prolongation
of progression free survival was observed in these studies. However, the majority of them
included only small patient cohort and did not design the case controls properly. Due to
these shortcomings bevacizumab has not been approved as a GBM therapy in Europe. In
contrast, bevacizumab has been approved as standard care for recurrent glioblastomas in
United States. This decision was especially encouraged by the increase in overall survival (9,2
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months in bevacizumab treated vs 8,7 months in control group) observed in one study
(Friedman et al., 2009).
To further evaluate the efficacy of bevacizumab in newly diagnosed GBM, two large, properly
case controlled trials were recently conducted (Chinot et al., 2014; Gilbert et al., 2014). In
these trials the bevacizumab treatment was combined with standard TMZ treatment. In
neither of the trials the pre-set criteria for successful study were met. A subtle increase in
progression free survival was observed but the overall survival was not improved. It has been
suggested that the bevacizumab treatment may alter the glioblastoma phenotype into more
invasive which gives an advantage for the tumor cells to escape the therapy (Baker et al.,
2014). In addition, the invasive tumor type is more difficult to locate in MRI and may result
in false prolongation of progression free survival. Moreover, the tumor cells might adapt to
the hypoxic tumor environment and change their metabolism towards glycolytic cycle and
thus gain resistance to bevacizumab (Fack et al., 2015).
In addition to bevacizumab, targeting of the integrins and EGF receptor have been
investigated as treatment options for GBM (reviewed in (Chen et  al., 2016) ). However,
neither of these have been successful so far. More studies need to be conducted to fully
understand the consequences and benefits of the targeted therapies in glioblastoma. In
future trials, the increased knowledge of the molecular subclasses of GBM should be
considered and may lead to more personalized treatment options.
2. Glioblastoma stem cells 
2.1. Cancer stem cell hypothesis 
Normal tissues contain a population of undifferentiated stem cells that are capable to
differentiate into diverse cell types within an organism. In normal conditions, the stem cells
divide asymmetrically which means that they give rice to one stem cell daughter cell and one
differentiated daughter cell (Morrison and Kimble, 2006). This way they can maintain the
stem cell number as constant while still providing new differentiated cells for the tissue. This
is a key mechanism to regenerate tissues.
The cancer stem cell hypothesis originates from the investigation of hematological
malignancies. It assumes that cancers consist of two types of tumor cells: stem-like cells and
differentiated, bulk tumor cells. Similarly as normal stem cells in tissues, the population of
the  stem-like  cancer  cells  is  smaller  but  they  are  responsible  for  maintaining  the  tumor
whereas  the  bulk  tumor  cells  make  up  the  most  of  the  tumor  volume.  Acute  myeloid
leukemia initiates when genetic aberrations occur in the hematopoietic stem cells (HSC) or
committed progenitor cells increasing their self-renewing capability (Bonnet and Dick, 1997).
The transformed HSCs divide according to the hierarchical cell division mode of the normal
HSCs  but  cannot  give  rise  to  normal  progeny.  Instead,  they  give  rise  to  tumorigenic
progenitor cells and thereby maintain the leukemia (Bonnet and Dick, 1997). Later on, similar
observations of oncogenic stem cells have been made in solid tumors including breast, colon,
pancreatic and lung cancers (reviewed in (O'Brien et  al., 2009)). These mutated tumor
maintaining cells are termed cancer stem cells (CSC) (Clarke et  al., 2006). They share
similarities with their stem cell counterparts of normal tissues. Their most important features
are their ability to self-renew, to differentiate into non-tumorigenic cancer cells, to
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phenocopy the original tumor of the patient and the capability to initiate tumor growth in
rodents (Clarke et al., 2006).
2.2. Discovery and characterization of glioblastoma stem cells 
Like other solid tumors also GBMs are heterogeneous and contain populations of
differentiated tumor cells and cells harboring similarities with neural stem cells. The
nomenclature of the CSC population in GBMs has not been standardized. These cells are
often called glioblastoma stem-like cells, glioma initiating cells, tumor propagating cells,
glioma stem cells and glioblastoma stem cells. Here this cell population is referred to as
glioblastoma stem cells (GSCs).
The first indication of GSCs was discovered in cultured human and rodent GBM cells when
they were detected to be expressing neural stem cells markers nestin and CD133 under in
vitro culture conditions (Ignatova et al., 2002; 2002; Kondo et al., 2004; Singh et al., 2003).
These cells were also capable of self-renewing. Next, GSCs were isolated from patient-
derived brain tumors simultaneously in two independent studies. One study isolated GSCs
based on their expression of CD133 (Singh et al.,  2004). It was observed that already 100
CD133-positive cells were able to initiate brain tumor when implanted into mice in contrast
to  100  000  CD133-negative  cells  that  did  not  initiate  tumors  at  all.  Furthermore,  the
xenografted tumors successfully recapitulated the characteristics of the original human
tumor. In the other study human primary brain tumor cells were cultured in vitro under
conditions that were known to maintain neural stem cells (Galli et al., 2004). Isolated tumor
cells were then transplanted into mice where they effectively formed tumors that
recapitulated GBM hallmarks. In addition, the cells were able to differentiate into astrocyte-
like, neuron-like and oligodendrocyte-like tumor cells in vitro. Serial transplantation of these
cells also proved their ability to self-renew and maintain the tumor.
After the first studies identifying the GSC populations within GBM tumors, numerous studies
have tried to further characterize these cells. The neurosphere culture system where cells
are kept under serum free conditions supplemented with recombinant EGF and FGF has been
widely accepted method for passaging of the GSCs (De Witt Hamer et al., 2008; Lee et al.,
2006). Using this culture system the GSCs can be derived from fresh GBM biopsies
(Hasselbach et al., 2014a). In addition, laminin coated cell culture plates have been suggested
to be a reliable method for adherent GSC culture conditions (Pollard et al., 2009). Using rat
GBM models it has been proposed that the long-cultured cell-lines also contain a small
population of GSCs and could be used as a source for the GSCs (Kondo et al., 2004). However,
this observation was later challenged because the cell-line derived GSCs do not resemble the
characteristics of GSCs freshly isolated from the patient tumors (Ahmad et al., 2014; De Witt
Hamer et al.,  2008). Therefore, freshly isolated cells are thought to be a better source of
GSCs.
Neural stem cells reside in a specialized niche in the subventricular zone and hippocampus
in the adult mammalian brain (Doetsch et  al., 1999; Johansson et  al., 1999). The niche
provides favorable growth conditions for the stem cells. Within the niche the stem cells are
nurtured and kept under undifferentiated state. The neural stem cells are often in contact
with the microvessels of the niche. These vessels lack the blood-brain barrier and thus are
able provide nutrients and growth factors to the stem cells (Shen et al., 2008; Shen et al.,
2004; Tavazoie et al., 2008). Furthermore, the ability to grow under hypoxic condition is a
21
typical feature of the stem cells. In human brain the oxygen concentration varies from 0.55%
in the midbrain to 14% on the surface of the brain (De Filippis and Delia, 2011). Since the
neural stem cell niche locates deep inside the brain it is relatively hypoxic. The hypoxia
activates pathways that regulates the maintenance and self-renewal of the neural stem cells
(Gustafsson et al., 2005; Hu et al., 2011).
The GSCs have been observed in various locations within the GBM tumors suggesting that
there may be different niches for them. Like the neural stem cells, also the GSCs reside in
hypoxic regions within the GBM tumors. In fact, hypoxia is an important factor responsible
for the maintenance of the GSCs. It promotes the self-renewal and maintenance of the GSCs
and  even  reprograms  the  bulk  tumor  cells  into  more  stem-like  state  (Bar et  al., 2010;
Heddleston et al., 2009; Inukai et al., 2015). The response for hypoxia may be regulated by
both HIF1α and HIF2α proteins. HIF1α expression was upregulated in majority of GBM cells
in the hypoxic regions (Li et al., 2009; Soeda et al., 2009) whereas HIF2α was upregulated
specifically in CD133-positive GSCs (Li et al., 2009). HIF2α was upregulated in the GSCs even
upon minor changes in the oxygen balance whereas HIF1α upregulation was observed only
under severely hypoxic conditions (Li et al., 2009). Interestingly, silencing of HIF2α reduced
GSC ability to initiate tumors in mice (Li et al., 2009) suggesting that hypoxia may be a critical
factor for the growth of the GSCs. Furthermore, this interplay of various HIF proteins may
give advantage for the GSCs to survive within the tumor core.
Paradoxically, GSCs reside also on perivascular niches next to tumor microvasculature
(Calabrese et al., 2007; Charles et al., 2010; Lathia et al., 2010). In normal tissues the blood
vessels are the source for oxygen and maintain the correct tissue homeostasis. Therefore, it
is possible that the tumor vessels provide oxygen or other nutrients to GSCs similarly to the
normal neural stem cells. However, the abnormal vasculature of the GBM does not function
properly. Despite the excessive tumor angiogenesis the GBM tissue remains hypoxic or even
anoxic (Rampling et  al., 1994). Therefore, the proximity to vasculature may offer other
benefits for the GSCs. Indeed, the endothelial cells were observed to produce nitric oxide
that promoted the maintenance and self-renewal of the GSCs via activating Notch pathway
(Charles et al., 2010). In vivo, inhibition of the nitric oxide production inhibited tumor growth
in spontaneous glioma mouse model (Charles et al., 2010). Furthermore, endothelial cells
also expressed Notch ligands that activate the pathway leading to increased self-renewal of
GSCs (Zhu et al., 2011).
2.3. Contribution of glioblastoma stem cells to the tumor malignancy 
The GSCs have been connected to several aspects that contribute to the lethality of GBM.
Because the GSCs show enhanced capability to give rise to brain tumors in mice even when
implanted in very low numbers (Singh et al., 2004), they are thought to be the GBM initiating
cells. Furthermore, somatic mutations introduced to neural stem cells are enough to induce
spontaneous brain tumor formation in mice (Alcantara Llaguno et al., 2009).
The GSCs exhibit increased resistance to radiation therapy. They rapidly activate the DNA
damage checkpoint after radiation therapy via L1-CAM mediated activation of c-MYC (Bao et
al., 2006a; Cheng et al., 2011b). In addition, they simultaneously activate the G2-M cell-cycle
checkpoint after the exposure to the radiation (Ahmed et  al., 2015). This gives them
advantage to avoid the radiation induced cell death. Therefore, the concordant inhibition of
cell-cycle checkpoint and DNA repair machinery may sensitize the GSCs to radiation therapy
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(Ahmed et  al., 2015). Furthermore, the GSCs show increased resistant towards TMZ
chemotherapy. This has been investigated utilizing a genetic glioma mouse model where
neural stem cells were labeled with nestin-GFP transgene and bred with genetically
engineered mouse model that harbors mutations in p53, NF1 and PTEN (Chen et al., 2012).
These mice spontaneously form astrocytic tumors with full penetrance (Alcantara Llaguno et
al., 2009; Chen et al., 2012). Interestingly, the tumors that arose contained two type of cells:
proliferative, GFP-negative tumor cells and stem cell like, non-proliferative, GFP-positive
cells. When TMZ was administered to the mice the GPF-negative cells died while GFP-positive
cells persisted and even gave rise to new tumors (Chen et al., 2012). This suggests that the
GSCs are resistant to the TMZ-therapy possibly due to their slow proliferation rate.
Moreover, via their capability to give rise to tumorous progeny they may cause the tumor
relapse.
The normal neural stem cells are typically passive cells that remain in their niche under
normal conditions (Kazanis, 2012). However, during pathological conditions they actively
migrate to the sites of injury (Kazanis, 2012; Kojima et al., 2010). Similarly, the GSCs show
increased potential for motility. When GSCs were implanted into mice brain they produced
more invasive tumors than their non-stem-like counterparts (Cheng  et al., 2011a). In human
tumor biopsies and xenograft models the GSCs have been located to the invasive tumor front
suggesting that they play a role in the spreading of the tumor (Cheng et al., 2011a; Kitai et
al., 2010). Furthermore, they expressed various proteases that are known to facilitate cell
migration (Cheng et al., 2011a). In vitro upregulation of nestin has indeed been connected
to enhanced invasive potential of glioma cells (Ishiwata et al., 2011).
The relationship between the vasculature and the GSCs may be mutually beneficial. GSCs can
secrete vascular endothelial growth factor that can induce the tumor angiogenesis (Bao et
al., 2006b). Interestingly, the GSCs may possess capability to transform into endothelial cells
or to pericytes that cover the vessel walls (Cheng et  al., 2013; Ricci-Vitiani et  al., 2010).
Furthermore, the GBM tumors exhibit vasculogenic mimicry, a process in which tumor cells
form tubular structures that resemble blood vessels. The GSCs may form these tubes and
enhance the tumor blood flow (Chiao et al., 2011; El Hallani et al., 2010; 2010). However,
this phenomena has been challenged by suggesting that rather than transforming into
endothelial cells the GSCs are capable of fusing with the existing endothelial cells and
forming hybrid vessels (El Hallani et al., 2014). This aids the growth of the tumor vasculature
which is responsible for providing the oxygen and nutrient supply to the tumor and thus
promotes the tumor growth.
2.4. Controversies in the glioblastoma stem cell hypothesis 
In a majority of the investigations conducted so far the identification of the GSCs is based on
marker proteins that the cells express. The first markers used for describing the GSC
population were CD133 and nestin. They were both promising candidates because they are
expressed by the neural stem cells and both of their expression is associated with poor
patient survival (Zhang et al., 2008). Furthermore, CD133 proved out to be essential for GSC
maintenance since silencing of CD133 reduced the proliferation and self-renewal capability
of the GSCs (Brescia et al., 2013). However, the role of CD133 as a universal marker for the
GSCs was challenged once it was observed that also CD133-negative cells were able to form
tumors in rodents (Beier et al., 2007; Wang et al., 2008). In addition, the CD133-negative
cells were able to give rise to CD133-positive cells in rats (Wang  et al., 2008). This observation
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was partly explained by the finding that the CD133 can shuttle between the plasma
membrane and cytoplasm of the cells (Brescia et al., 2013). Majority of the experiments in
which the GSCs are pooled based on CD133 utilize fluorescent activated cell sorting based
on membranous CD133 expression. Therefore, these studies could miss the GSCs population
where CD133 is cytoplasmic at the time of sorting.
After  that,  several  new  GSC  markers  have  been  searched  in  hopes  of  clarifying  the
characterization of the GSCs. Mostly proteins that are expressed by the normal neural stem
cells have been considered as potential markers. The suggested proteins include several
transcription factors NANOG, OCT4, SALL4, SOX2, STAT3, Olig2, Bmi1, c-Myc, KLF4 and cell
adhesion receptors CD44, L1CAM, integrin alpha6 and CD15 (reviewed in (Bradshaw et al.,
2016) ). However, none of these markers have been exclusive in describing the GSC
population still today. Based on genetic profiling the GBMs consist of both diploid and
aneuploid cells which have different tumorigenic properties in vivo (Stieber et al., 2014). The
aneuploid cells formed tumors more aggressively in mice and resulted in shorter survival
times. Since the enhanced tumorigenity is characteristic for GSCs it could be expected that
they are mostly aneuploid cells. However, when the GSCs were isolated using different cell
surface markers the percentage of the diploid and aneuploid cells within the cell pool varied
(Stieber et al., 2014). The ratio of the diploid and aneuploid cells was altered depending on
the marker used for the sorting. This suggests that the separation of the GSC population
based on cell surface markers cannot discriminate the genetic heterogeneity within the
tumor. Therefore, new studies and methods to isolate and characterize the GSCs are needed.
Furthermore, it should be considered if stemness could be discriminated by a functional
criteria instead of specific markers.
Furthermore, the hierarchical cell division theory of the GSCs has not been proved. Recent
report studying the matching pairs of GSCs and their differentiated tumor cell counterparts
suggest that most of the GBM cells have the capability to present stem cell characteristics
depending on the environment (Schneider et al., 2016). Moreover, both the hypoxic tumor
environment and the FGF secreted by adjacent endothelial cells were capable of
reprogramming the differentiated tumor cells into more stem like state (Fessler et al., 2015).
Therefore, it still remains unsolved whether all the GBM cells possess stem-like cell
properties or whether the GSCs are a separate pool of cells within the tumor.
3. Netrins 
Netrins constitute a conserved family of extracellular matrix proteins. They have been named
after a Sanskrit word netr which means the one who guides. Five secreted netrins, (NTN1-5)
and two membrane bound forms (NTN-G1 and NTN-G2) have been discovered in vertebrates
(Nakashiba et al., 2002; Serafini et al., 1996; Serafini et al., 1994; Yamagishi et al., 2015; Yin
et al., 2000). NTNs 2 and -3 are homologous to each other. NTN2 is expressed in avians and
zebrafish while NTN3 is the counterpart in mammals. Uncoordinated-6 (UNC6) and netrin-A
and -B (NetA and –B) represent the Caernohabtidis elegans (C. elegans) and Drosophila
melanogaster (D. melanogaster) counterparts of the vertebrate NTNs (Harris et al., 1996;
Mitchell et al., 1996a). NTN1 is the prototype of the family and is most widely studied.
Structurally NTNs resemble laminins and consist of three distinct domains: N-terminal,
central and C-terminal domains (figure 3). The N-terminal domain of NTNs 1-3 and NTN-G1-
2 is homologous to laminin gamma chain whereas in NTN4 it resembles laminin beta chain
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(figure 3). The central part of NTNs contains three EGF repeats homologous to laminin
domain VI (Serafini et al., 1994). On the contrary, the C-terminal domain, called NTR domain,
is not related to the laminin domains. This domain shares similarity with the C-termini of
complement proteins, Frizzled-related proteins, type I collagen C-proteinase enhancer
proteins, and tissue inhibitors of metalloproteinases (Banyai and Patthy, 1999). Additionally,
the membrane bound NTN-Gs have glycosylphosphatidylinositol anchor in their C-terminal
tail (Nakashiba et al., 2002). Furthermore, the newly found member of the family, NTN5 lacks
the N-terminal domain and one of the EGF repeats (Yamagishi et al., 2015).
Within this thesis the functions of NTN1 and -4 in glioblastoma were investigated. Therefore
their basic functions during development and cancer are reviewed in the following chapters.
Figure 3. Schematic illustration of the structure of netrins. I: N-terminal domain related to
laminin γ-chain, II: 3 EGF repeats, III: NTR domain, IV: N-terminal domain related to laminin
β-chain, ~: GPI-anchor
 
3.1 Various roles of Netrins in development 
3.1.1. Netrin-1 in axon guidance 
NTNs were first investigated in C. elegans where the loss of UNC6 resulted in defects in axon
pathfinding (Brenner, 1974; Hedgecock et  al., 1990). Subsequently, similar defects were
discovered in vertebrates upon partial NTN1 deletion (Serafini et al., 1996). Recently, these
findings were confirmed utilizing a mouse model exhibiting complete loss of NTN1. It was
found to be embryonically lethal approximately by embryonic day 14.5 due to the failed axon
pathfinding (Bin et al., 2015).
NTN1 plays a dual function in axon guidance: it can either act as axon attracting or repelling
cue (Hong et al., 1999). These effects are mediated via two receptor families: the deleted in
colorectal cancer (DCC) family that contains DCC and neogenin receptors (Engelkamp, 2002;
Keino-Masu et  al.,  1996)  and  the  uncoordinated-5  (UNC5)  family  comprised  of  UNC5A-D
(Leonardo et  al.,  1997).  The  axon  attracting  effects  appear  to  be  mediated  via  the  DCC
receptors in coordination with the Down syndrome cell adhesion molecule (DSCAM) and
repellent effects via binding to the UNC5 receptors (Keino-Masu et al., 1996; Leonardo et al.,
1997; Ly et al., 2008).
25
The axons sense their environment via specialized structures called growth cones, which are
very motile and responsive to many extracellular guidance signals (Geraldo and Gordon-
Weeks, 2009; Kolodkin and Tessier-Lavigne, 2011; Lowery and Van Vactor, 2009). The shape
of the growth cones resembles human hand: it contains spike like filopodial protrusions and
sheet like lamellipodia between the spikes. The growth cones undergo fast changes during
the axon guidance. These structural changes are dependent on the microtubule and actin
dynamics within the growth cone (Geraldo and Gordon-Weeks, 2009). To be able to turn the
growth cone must be able to grow from the other side while retracting from another.
Because the axon extensions are very far away from the cell body and nucleus, it is essential
that the proteins needed for the growth of the axon can be produced locally (Piper et al.,
2015). In this process the microtubules are needed for polypeptide chain elongation and for
the delivery of ribonucleoparticles whereas the F-actin is needed for the initiation of the
protein synthesis.
These growth cones are responsive to a diffusive NTN gradient secreted by the floor plate
cells  in  the  developing  embryo.  NTN1  acts  as  a  polarizing  agent  which  leads  to  DCC  and
DSCAM clustering and to the coupling of microtubules on one side of the growth cone (Huang
et al., 2015; Jain and Welshhans, 2015; Qu et al., 2013; 2013). These receptors then function
as signaling platforms, which can regulate both the local protein synthesis and microtubule
growth to orient the axon steering (Piper et al., 2015; Tcherkezian et al., 2010). When the
axon crosses the midline it starts to express UNC5 receptor and its response to NTN1 changes
to repulsive (Leonardo et al., 1997). This allows the elongation of the axon on the other side
of the embryo.
3.1.2. Functions of netrins in the morphogenesis of epithelial structures  
In  addition  to  axon  guidance,  NTNs  have  been  suggested  to  play  a  role  in  several
developmental processes of various epithelial structures. During lung development NTN1-
and -4 are expressed by the epithelial cells on the stalk area of the developing lung bud
(Dalvin et  al., 2003; Liu et  al.,  2004).  After  secretion  NTNs  accumulate  to  the  basement
membrane or to the epithelial cells located behind the tip cells (Liu et  al., 2004). UNC5B
receptor has opposite expression pattern than NTNs and is expressed by the tip cells of the
budding lung. In addition, the tip cells show increased phosphorylation of ERK-proteins.
Interestingly, the addition of exogenous NTN to 3D-lung bud cultures abolish the budding or
even reverse its direction towards the lumen of the lung bud (Liu et  al.,  2004).  It  also
decreases the overall levels of phosphorylated ERK. This suggests that NTNs at the stalk area
prevent the lung bud formation by reducing ERK phosphorylation. Authors examined
possible receptors involved and suggest UNC5B to mediate this cascade but do not
exclusively rule out integrins or other NTN receptors.
During mammary gland development NTN1 is expressed at preluminal cells of terminal end
buds (Srinivasan et al.,  2003).  Neogenin  on  the  other  hand  is  expressed  by  cap  cells
neighboring the preluminal cells. During this process mammary gland branches elongate via
growth of the cap cells on the terminal end buds. It is important that the terminal end bud
keeps its correct organization where the cap cells are in contact with the luminal cells behind
them (Silberstein, 2001). In mammary glands where both NTN1 and neogenin are deleted,
the cap cells move uncoordinatedly and creat gaps between the luminal cells and the cap
cells (Srinivasan et al., 2003). In addition, mammary glands lacking NTN1 or neogenin display
loss of adhesion between the cap and luminal cells although their expression of E- and P-
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cadherin remain normal. Therefore NTN1-neogenin interaction may be important stabilizer
of the epithelial cell adhesions.
In developing pancreas NTN1 is expressed in various populations of epithelial cells in ductal
structures, developing islet cells and around undifferentiated acinar structures (Yebra  et al.,
2003) whereas NTN4 is expressed in blood vessels within ductal structures (Yebra et  al.,
2011). However, both NTN1 and NTN4 serve as adhesive surface to pancreatic epithelial cells
(Yebra et  al., 2003; Yebra et  al., 2011). NTN1 and alpha6beta4 and alpha3beta1 integrin
receptors co-localize on the surface of the epithelial cells. Furthermore, NTN1 binding to
integrins via its C-terminal domain mediate the migratory effects (Yebra et al., 2003). The
two integrin receptors co-operate in binding to NTN1 and possibly activate c-MET receptor
and subsequent epithelial cell migration pathways. NTN1 induces the migration in a
haptotactic manner only and not chemotactically as during axon guidance. Interestingly,
majority of the cells migrating along NTN1 are undifferentiated pancreatic progenitor cells.
Similarly, NTN4 is observed to bind to integrins alpha2beta1 and alpha3beta1 (Yebra et al.,
2011). This binding induces the expression of several cell differentiation related genes
suggesting that NTN4 is controlling the differentiation of pancreatic epithelial cells. (Yebra et
al., 2011).
During invertebrate development, NTN acts as polarizing factor. Migration of specialized
gonadal cell, anchor cell, of C. elegans is dependent on the guidance of UNC-6 and UNC-40,
C. elegans counterparts for NTNs and DCC, respectively (Hagedorn et al., 2013; Sherwood
and Sternberg, 2003; Ziel et al., 2009). UNC-6 clusters to the basement membrane through
which the anchor cell invades to reach the vulval epithelium and creates vulval-uterine
connection. Contact of anchor cell with UNC-6 leads to rapid polarization of the anchor cell
which then allows it to invade through the basement membrane cells (Wang et al., 2014).
During the polarization UNC-40 receptors cluster to the site of UNC-6 source, followed by
the modulation of the F-actin cytoskeleton. This clustering marks the place for the invasive
protrusion.
During the development of D. melanogaster NTNs are involved in the development of the
midgut. First, two masses of mesenchymal primary midgut epithelial cells (PMEC) are located
in the opposite ends of the embryo (Tepass and Hartenstein, 1994). They start to migrate
towards each other along the visceral mesoderm cells that reside on the outer membranes
of  the embryo (Tepass  and Hartenstein,  1994).  In  the course of  the migration the PMECs
undergo mesenchymal to epithelial transition and form epithelium (Tepass and Hartenstein,
1994). The visceral mesoderm cells secrete NetA and -B (D. melanogaster counterparts for
NTNs)  while  the  PMECs  express  NTN  receptor  Frazzled  (D. melanogaster counterpart for
DCC) (Mitchell et  al.,  1996b).  NetA  and  –B  function  parallel  on  this  process  and  are
responsible for maintaining the motility and correct shape of the migrating PMECs.
Moreover, they induce the polarization and subsequent mesenchymal to epithelial transition
of the PMECS. This is mediated via the clustering of Filamin-1, F-Actin and E-cadherin to the
contact points with the visceral mesoderm (Pert et al., 2015).
3.2. Netrins in cancer 
3.2.1. Netrin-1 as a regulator of cancer cell invasion 
NTN1 has been linked to the motility of numerous cancers (table 1). These include both
epithelial cancers including colorectal, breast, pancreatic and hepatocellular cancers. In
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addition, NTN1 has been linked to the progression of nervous system cancers such as
medulloblastoma and neuroblastoma. NTN1 has various effects to cell behavior and will be
discussed in more detail in following sections.
Table 1. Netrin-1 expression and functions in various cancers. + expression has no change
in comparison to normal tissue, ++ modest increase, +++ strong upregulation and − indicates
decreased expression level (modified from (Ylivinkka et al., 2016))
Cancer type Colon Breast Pancreatic Lung Liver Medullo-blastoma
Neuro-
blastoma
Ex
pr
es
sio
n
in
tu
m
or
tis
su
e
low grade/
non-metastatic
tumors
N/R + - +++ +++ N/R N/R
high grade/
metastatic
tumors
+++ +++ +++ +++ +++ +++ +++
brain
metastases + ++ N/R +++ N/R N/A N/A
Ef
fe
ct
s
protection from
apoptosis x x x x N/R x x
motility
promoting
effect
x x x x x x x
suggested as
biomarker N/R N/R x N/R N/R x x
3.2.1.1. Epithelial cancers 
In  a  majority  of  colorectal  cancers  both  DCC  and  UNC5  receptors  are  downregulated
(reviewed in Mehlen and Tauszig-Delamasure, 2014). However, the majority of tumors are
expressing NTN1 (Paradisi et al., 2008). In addition, colon carcinoma and adenoma cell lines
show upregulated expression of NTN1 whereas the expression of DCC or UNC5 receptors
were downregulated (Paradisi et  al., 2008; Rodrigues et  al., 2007). NTN1 upregulation
promots invasiveness and growth of the cancer cells lacking DCC both in vitro and in vivo
(Rodrigues et al., 2007). The invasion promoting effects of NTN1 were mediated via RhoA,
Rac1, Cdc42 and PI3K signaling. On the contrary, DCC acts as a tumor suppressor gene by
reducing cancer cell invasion and metastasis in vivo (Rodrigues et al., 2007). DCC expressing
tumor xenografts hava same growth potential as control tumors but invade significantly less
to lymph nodes or to lungs of the mice (Rodrigues et al., 2007). Furthermore, under hypoxic
conditions DCC expression increas the percentage of apoptotic cells but not under normoxic
conditions. Interestingly, NTN1 upregulation can not rescue DCC induced apoptosis
(Rodrigues et al., 2007) supporting the pro-invasive rather than survival promoting function
of NTN1.
In breast cancer NTN1 is expressed especially in the metastatic cell lines (Fitamant et  al.,
2008). When NTN1 expression was analyzed in human tumor biopsies it was strongly
expressed in tumors with lymph node or other distant organ metastasis while tumors that
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were restricted to breast area displayed only modest expression (Fitamant et  al., 2008).
Furthermore, NTN1 expression was analyzed in two mouse breast cancer cell lines, 67NR and
4T1, which differ in their metastatic capability. Interestingly, the non-metastasizing 67NR cell
line has lower NTN1 expression than metastatic 4T1 cell line. Expression pattern of classical
NTN receptors does not differ between these cell lines. These finding suggest a pro-invasive
role for NTN1 in breast cancer but the cellular mechanisms remain largely unknown.
Moreover, NTN1 expression has been found to increase pancreatic ductal adenocarcinoma
(PDAC) cell invasiveness and apoptotic resistance. In addition, it serves as adhesive surface
for the cells in vitro (Dumartin et al., 2010). NTN1 was also observed to mediate the neural
invasion of PDAC in a mouse model (Wang et al., 2015). The expression of NTN1 is regulated
via NFkb signaling activation (Wang et  al., 2015) similarly as observed previously during
colorectal cancer progression (Paradisi et al., 2008; Paradisi et al., 2009). In addition, NTN1
also serves as prognostic factor in pancreatic cancer (Link et al., 2007). On the contrary, a
recent study suggest NTN1 to be a tumor suppressor in low-grade pancreatic
adenocarcinoma via suppressing growth by UNC5B mediated integrin beta4 downregulation
(An et  al., 2016). However, NTN1 upregulation is observed in higher grade pancreatic
adenocarcinomas correspondingly to previous studies (An et al., 2016).
Moreover, NTN1 increases the proliferation and migration of hepatocellular carcinoma cells
(Qi et al., 2015). During NTN1 treatment the cancer cells upregulate yes associated kinase
(YAP), an oncogene that belongs to the Hippo signaling pathway (Qi et  al., 2015).
Furthermore, under hypoxic conditions NTN1 induced epithelial to mesenchymal transition
and upregulation of invasion promoting inflammatory molecules of the hepatocellular
cancer cells (Han et al., 2015; Yan et al., 2014).
3.2.1.2. Cancers of the neural system 
NTN1 may promote also the invasiveness of tumors of the nervous system. Its expression
increases the invasiveness of medulloblastoma cells via neogenin and UN5B receptors (Akino
et al., 2014). Increased levels of NTN1 have been detected in the urine of medulloblastoma
patients. Surgical resection of the tumor significantly decreases the levels of NTN1 in the
urine suggesting a potential role as a biomarker for NTN1 (Akino et al., 2014). Interestingly,
in subcutaneous medulloblastoma mouse xenograft model NTN1 upregulation also increases
the vascularity of the tumors (Akino et al., 2014). These findings indicate a role for NTN1 in
the progression of tumors in the nervous system.
In an extracranial neural tumor, neuroblastoma, the expression of NTN1 in tumor tissue is
associated with poor patient prognosis (Delloye-Bourgeois et al., 2009b). NTN1 is strongly
expressed in aggressive, stage 4 neuroblastoma. On the contrary, expression of the DCC
receptor  is  low  and  UNC5A-B  modest  in  these  tumors.  NTN1  expression  is  connected  to
increased apoptosis resistance of the neuroblastoma cells (Delloye-Bourgeois et al., 2009b).
Interestingly, NTN1 inhibition also leads to a decrease in the migratory capacity of the
neuroblastoma cells. In a mouse model where NTN1 negative primary neuroblastoma
tumors were xenografted into mice the emerging metastatic lesions in lungs or heart are
NTN1 positive. This raises the question: why is NTN1 upregulated during the metastatic
cascade? Does NTN give advantage in this process? Authors suggest that NTN1 expression
allows the tumor cells to survive better outside the primary tumor (Delloye-Bourgeois  et al.,
2009b). However, considering the evidence of the proinvasive nature of NTN1 in epithelial
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cancers it may regulate the invasiveness of neuroblastoma as well. Moreover, a recent study
suggests that NTN1 is an independent prognostic factor in brain metastases of various
cancers including non-small cell lung cancer, breast cancer and melanoma (Harter et  al.,
2014).
In  the  light  of  these  observations  NTN1  seems  to  be  strongly  linked  to  cell  invasion  and
metastatic growth. However, not much is known about NTN1 driven molecular mechanisms
in cancer cell invasion. Since in many cancers the expression of NTN1 and DCC or UNC5 does
not correlate there may be novel signaling pathways mediating the effects of NTN1.
3.2.2. Netrin-4 has a dual function in tumorigenesis 
Besides  NTN1,  also  NTN4  is  connected  to  cancer  cell  invasion.  However,  its  role  is
contradictory: some reports indicate that NTN4 is a negative regulator of tumor cell motility
while others report the opposite.
In breast cancer NTN4 is downregulated in majority of primary tumors while upregulated in
invasive tumor cells (Esseghir et  al.,  2007).  Similarly,  NTN4  is  upregulated  in  breast  and
Müllerian carcinoma effusions (Yuan et al., 2011). NTN4 inhibition by microRNA miR-196a
results in lowered proliferation and migration rates of cervical cancer cells (Zhang et  al.,
2013).  Upregulation of NTN4 expression is also observed in invasive glioblastoma cells when
compared to tumor core (Hoelzinger et  al., 2005). Furthermore, NTN4 upregulation in
invasive melanoma tumors was recently reported (Jayachandran et al., 2016). Silencing of
NTN4 decreases melanoma cell invasiveness in vitro and in vivo. In  gastric  cancer  NTN4
mediates the proliferation and motility of cancer cells in vitro via neogenin receptor (Lv et
al., 2015). NTN4 expression in human gastric cancer biopsies is also associated with poor
patient prognosis (Lv et  al., 2015). This observation is in discordance with previous study
where the upregulated NTN4 expression in breast cancer biopsies predicts patient prognosis
(Esseghir et al., 2007).
On the contrary, NTN4 protein expression has been also linked to tumor suppressor
functions. When screened in a variety of cell-lines NTN4 expression is observed to be higher
in normal cells, such as endothelial and epithelial cells and fibroblasts than in transformed
cancer cell lines (Nacht et al., 2009). Furthermore, the addition of exogenous NTN4 has little
effect on primary cells but inhibited proliferation of cancer cell lines. Interestingly, all cells
are responsive to low concentrations of recombinant NTN4 but increasing concentrations
show inhibitory effects. In addition, tumor growth suppressing functions of NTN4 have been
observed in colorectal cancer in vivo (Eveno et al., 2011; Eveno et al., 2013). Upon NTN4
overexpression in colorectal carcinoma cells growth of the primary tumor is suppressed in
mouse xenograft model (Eveno et al., 2011; Eveno et al., 2013). Moreover, the number of
liver, lung and lymph node metastases is decreased too (Eveno et al., 2013). NTN4 expressing
tumors show less tumor angiogenesis and more apoptosis among the tumor cells (Eveno et
al.,  2011).  However,  exogenous  NTN4  addition  does  not  affect  cancer  cell  apoptosis  or
proliferation in vitro. Therefore, authors suggest that the effect on the primary tumor is due
to the reduced tumor angiogenesis.
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3.2.3. Netrins as tumor cell survival factors 
NTNs have been implicated to act as survival factors in many forms of cancer. Based on these
observations Mehlen and colleagues have presented dependence receptor hypothesis
where the proapototic functions of the NTN1 receptors are prevented by interaction with
NTN1 (Llambi et al., 2001; Mehlen et al., 1998; Mehlen and Bredesen, 2004). Both DCC and
UNC5 receptors contain so called death domain in their cytoplasmic tail. When the receptor
is not engaged with NTN1 the death domain is exposed and allows the binding of caspase-9.
This leads to caspase-3 activation and subsequent apoptosis. However, the caspase
activation sequence is prevented during the binding of NTN1 which leads to apoptosis
resistance. Therefore, NTN1 upregulation has been suggested to be a way to gain survival
advantage for several cancers including colorectal cancer, non-small cell lung cancer,
neuroblastoma and metastatic breast cancer (Delloye-Bourgeois et  al., 2009a; Delloye-
Bourgeois et al., 2009b; Fitamant et al., 2008; Mazelin et al., 2004).
4. Notch signaling  
In this thesis NTN1 was observed to interact with various components of Notch signaling
pathway. Furthermore, it was detected to induce Notch signaling. Therefore, the basics of
Notch signaling and its functions in GBM are discussed in the following chapter.
4.1. Basics of Notch signaling 
Notch receptors constitute a conserved family of transmembrane receptors. The name
originates from the phenotype of a mutant D. melanogaster that had notched wings. Four
receptors, Notch1-4 (Ellisen et  al., 1991; Lardelli et  al., 1994; Uyttendaele et  al., 1996;
Weinmaster et al., 1992), and five known ligands, Jagged1-2 and delta-like 1,-2 and 4 exist in
mammalians. The Notch proteins consists of a large extracellular domain containing 36
epidermal growth factor–like repeats, a single transmembrane domain, and an intracellular
domain containing a recombining binding protein suppressor of hairless (RBP-JK) -associated
molecule region, ankyrin domains, and a proline-glutamate-serine-threonine-rich region.
The Notch receptors are transcribed in the endoplasmic reticulum as pre-receptors (figure
4.). To yield active receptor they first undergo O-fucosylation in the endoplasmic reticulum
and  furin  cleavage  in  the  S1  site  at  the  Golgi  apparatus  (reviewed  in  (Haines  and  Irvine,
2003)). This is then followed by second glycosylation and transport to cell surface. Once the
receptor on the cell surface comes in contact with its ligand on neighboring, signal sending
cells it undergoes conformational change and a cleavage by ADAM10 or -17 proteinase
(Schroeter et al., 1998). The endocytosis of the ligand to the signal sending cell provides a
pulling force which then allows the intramembrane cleavage of the Notch receptor by
presenilin1 protease within the γ-secretase complex (Meloty-Kapella et al., 2012; Struhl and
Greenwald, 1999). The intracellular part of the receptor is endocytosed (Vaccari  et al., 2008)
and transported to the nucleus (Schroeter et  al., 1998). In the nucleus it binds to
mastermind-like 1 (MAML) and RBP-JK to form complex that activates transcription in the
target genes (Nam et al., 2006; Wilson and Kovall, 2006).
During developmental processes the Notch signaling pathway is one of the major regulators
of cellular differentiation. The tissues that are dependent on Notch include CNS,
hematopoietic system, vascular system, muscles, bones and several organs including heart,
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skin, kidneys, lungs and pancreas (reviewed in Artavanis-Tsakonas et al., 1995; Kopan and
Ilagan, 2009; Xu et  al., 2012). Furthermore, the Notch signaling has been connected to
several pathological conditions including various cancers, fibrosis, Down syndrome,
Alzheimer’s disease and multiple sclerosis (reviewed in Lobry  et al., 2011; Mathieu et al.,
2013; Xu et al., 2012) In this thesis, the Notch pathway functions have been studied in GBM
and thus it will focus on reviewing the functions of Notch signaling in GBM in more detail.
Figure 4. Notch signaling. Schematic illustration of the Notch receptor maturation and
activation. Modified from (Kopan and Ilagan, 2009)
4.2. Notch signaling in glioblastoma 
The  first  indications  of  the  importance  of  Notch  signaling  in  glioma  biology  were  the
observations of upregulated expression of Notch1, Jagged1 and Delta-like1 in several long
cultured GBM cell-lines and tissues of primary gliomas (Purow et al., 2005; Shih and Holland,
2006). In the glioma tissues strong nuclear Notch staining was detected, which indicated
activation of the signaling pathway (Purow et al., 2005). In addition, the conserved Notch-
target genes HES1 and HEY1 were expressed in all astrocytomas suggesting activated Notch
signaling within the tumors (Chen et al., 2010). Silencing of Notch1, Jagged1 or Delta-like1
with shRNAs in GBM cell-lines decreased their proliferation and tumorigenesis in mice
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(Purow et  al., 2005). Correspondingly, the inhibition of Notch signaling using γ-secretase
inhibitor (GSI) resulted in decreased proliferation of the GBM cell-lines (Chen  et al., 2010).
Interestingly, the different Notch receptors may have independent functions in gliomas.
Notch1 was observed to be expressed in all astrocytic tumors whereas Notch2 was expressed
selectively in a subset of the GBMs (Shih and Holland, 2006). Similarly, another studies noted
that Notch2 and Notch4 were highly expressed in GBM whereas Notch1 was more strongly
expressed in lower grade astrocytomas (Chen et al., 2010; Dell'albani et al., 2014). It was also
suggested that the expression of different Notch receptors could be used as markers for
glioma grading (Dell'albani et  al.,  2014).  Furthermore,  in  a  mouse model  where activated
Notch receptors were overexpressed in the eyes of embryonic mice, Notch3 receptor
showed most tumorigenic potential (Pierfelice et  al.,  2011).  The increase in  Notch1 or  -2
activation resulted in small tumors whereas active-Notch3 overexpression resulted in
glioma-like tumors that were invading towards the brain along the optic nerve (Pierfelice  et
al., 2011).
Notch signaling maintains the neural stem cells in undifferentiated state especially under
hypoxic conditions (Gustafsson et al.,  2005). Since the GBMs are also very hypoxic, Notch
signaling is an interesting candidate pathway for regulating the GSC maintenance. Indeed,
the first indications that Notch pathway is linked to the GSCs was made already during the
initial discovery of the GSCs. Upon genetic profiling of the newly characterized GSCs,
expression of Notch pathway candidates was detected with QRT-PCR analysis (Galli et al.,
2004).  Later  the  activation  of  the  Notch  signaling  in  these  GSCs  was  verified  by  HES1
expression that diminished upon GSI treatment (Fan et al., 2010). The treatment also blocked
cell proliferation and reduced the number of nestin- and CD133 positive cells via caspase-3
activation and subsequent apoptosis (Fan et al., 2010). Inhibition of Notch signaling by GSIs
also prevented the formation of neurospheres of primary GBM cells suggesting reduced
capability to maintain GSCs phenotype (Chen et al., 2010). Furthermore, the GSCs that have
high endogenous Notch activation are more sensitive towards the GSI treatment and
undergo cell cycle arrest and apoptosis upon the treatment (Kristoffersen et al., 2013). On
the contrary, it was reported that Notch inhibition would affect only the initial capability to
form the neurospheres but would not affect self-renewal or the clonogenity (Kristoffersen
et al., 2013).
Moreover, Notch pathway upregulation and enhanced nestin expression was observed (Shih
and Holland, 2006) in spontaneous glioma mouse model induced by constantly active Kras
(Holland et al., 2000). It was suggested that Notch signaling could promote the stemness and
nestin expression of the GBM cells. This observation was further validated in in vitro
conditions using U251MG cells. The forced upregulation of the Notch intracellular domain
upregulated nestin expression suggesting that nestin may be a transcriptional target of
Notch (Shih and Holland, 2006). Furthermore, both local administration of GSI and
pretreatment  of  GSC  cell-lines  with  GSI  reduced  the  capability  of  GSCs  to  initiate  tumor
growth in intracranial xenografts (Chen et al., 2010; Fan et al., 2010). GSI treatment also led
to the generation of more differentiated and angiogenic tumors (Kristoffersen et al., 2014).
Since the GSCs are more resistant to radiation and chemotherapy, inhibition of Notch
signaling is a putative way to sensitize the cells to treatment. Indeed, the GSI treatment
sensitized especially the GSC population to radiation (Wang et  al., 2010). Similarly,
knockdown of Notch1 or Notch2 increased the radiosensitivity of GSCs whereas the
introduction of constitutively active intracellular domains of Notch1 or Notch2 rescued the
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GSI induced sensitization (Wang et al., 2010). The inhibition of Notch signaling with GSIs in
combination with inhibition of another developmental pathway, Sonic Hedgehog, induced
the sensitivity of GSCs to TMZ treatment (Ulasov et  al.,  2011).  Furthermore,  the  GSI
treatment combined with radiation therapy and temozolomide prolonged the survival of
orthotopic glioblastoma (Yahyanejad et al., 2016).
In addition to the Notch signaling targeting via GSIs, it has been suggested that targeting the
transcription co-activator of Notch signaling would be more effective. Indeed, expression of
a dominant negative form of mastermind-like 1 protein caused G0/G1 cell cycle arrest and
induced apoptosis in GBM cell lines (Chen et  al.,  2010).  When LN428 cell  expressing this
dominant negative form of MAML protein were intracranially xenografted to mice the
resulting tumors had less Hes1 and Hes5 expression than control tumors suggesting reduced
Notch signaling (Chen et al., 2010). Furthermore, the GCSs express the RBPJ transcription
activator and require its expression for proliferation and self-renewal (Xie et al., 2016). In
addition, silencing of RBPJ in GSCs reduced their tumorigenic properties in vivo (Xie et al.,
2016).
Encouraged by these preclinical findings the GSIs have been also tested in clinical trials for
glioma treatment. To first clinical study patients with various advanced solid tumors were
recruited (Krop et  al.,  2012).  42 glioma patients  were also included to  the study.  Varying
dosages (450mg-4200mg) of GSI were orally administered to patients. Also the frequency
and length of treatment varied. The most beneficial treatment responses were observed
among the glioma patients: one patient with an anaplastic astrocytoma had a complete
recovery  and the survival  time of  10 other  glioma patients  prolonged (Krop et  al., 2012).
However, the patient cohort was too small to statistically evaluate the effects regarding the
survival of the patients. After these promising results another phase 0/I study was performed
aiming to investigate the ability of a GSI based drug to penetrate the blood brain barrier and
its effect to Notch signaling and to GSCs within GBM tumors (Xu et al., 2016). The evaluation
of the survival of the patients was not the primary objective and only 20 newly diagnosed
GBM patients were recruited to this study. GSI was administered as the only drug before
surgery and together with normal TMZ dosage and radiation therapy after surgical resection
of the tumor. In the study low toxicity was observed as was expected (Xu et al., 2016). The
compound penetrated the blood brain barrier well and successfully reduced the expression
of Notch signaling pathway components and target genes within the GBM tissue (Xu et al.,
2016). However, the concentration within the tumor tissue varied between patients.
Based on these findings targeting Notch signaling in human gliomas is an interesting
therapeutic target. More studies should be conducted to evaluate its clinical benefits. The
recent advances in the molecular subtyping of gliomas suggest that especially the patients
with classical GBM subtypes could benefit from the Notch inhibition therapy, as the tumors
within the classical subtype were characterized with highly expressed nestin, Notch pathway
components and Sonic Hedgehog signaling pathways (Verhaak et al., 2010). This should be
taken into consideration when planning new clinical trials.
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AIMS OF THE STUDY
Since NTNs are essential regulators of nervous system development, we hypothesized that
they might be important in human gliomas too. This was further supported by the findings
that NTN1 regulates several other cancers. At the time I started this research work nothing
was known about the roles of NTNs in human gliomas or glioblastomas. Therefore the major
aim was to identify receptors and signaling pathways of NTN1 and -4 in glioblastoma cells. In
the course of the studies my main interest shifted towards NTN1 and its involvement in the
regulation of GBM motility and stemness. This was initiated with the notion that NTN1 was
overexpressed in human GBM tumors and in invasive GBM cell-lines.
The specific aims of this work were:
1. To characterize the effects of NTN1 and NTN4 on glioblastoma cells (I, II, III)
2. To identify proteins interacting with and pathways mediating the effects of NTN1
and NTN4 (I, II)
3. To investigate the possible link between NTN1 and GBM invasiveness using in vitro
and in vivo models (II, III)
4. To explore how NTN1 is expressed in human gliomas, does the expression correlate
with patient prognosis and where it is localized in human glioma tissues (III)
5. To analyze if NTN1 is associated with the stemness of the GBM cells (III)
6. To decipher the mechanisms how engineered peptide, NTN1(II)FH, inhibits NTN1
signaling in GBM cells (II, III)
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MATERIALS AND METHODS
1. Cell lines 
The following cell lines were utilized. The articles in which the cell lines were used are
referred to with their roman numerals. Astrocytes, U87MG and 293FT cells were cultured
according to manufacturer’s instructions. U251MG and U373MG cell lines were cultured in
Dulbecco’s modified essential culture medium (DMEM) supplied with 10 % heat inactivated
fetal  calf  serum  (Gibco,  USA),  100  IU/ml  penicillin,  50  mg/ml  streptomycin  and  1%  L-
glutamine. GBM9 and GBM10 were isolated from fresh surgical GBM biopsies (see protocol
below) and cultured in serum free conditions in DMEM/F12 supplemented with 100 IU/ml
penicillin, 50 mg/ml streptomycin, B27 supplement, EGF 20ng/ml, FGF 20ng/ml.
Cell line Origin Source Article used in
Astrocytes human brain Lonza I, II
GBM10 human GBM established by us III
GBM9 human GBM established by us III
U251MG human GBM Health SciencesResource Bank, Japan I, II, III
U373MG human GBM DR. Bengt WestermarkUppsala I, II, III
U87MG human GBM ATCC I, II, III
293FT human embryonalkidney Invitrogen I, II, III
 
2. Reagents 
Name Purpose Manufacturer Articles usedin
rNTN1 recombinant human NTN1 R&D Systems III
rNTN4 recombinant human NTN4 R&D Systems I
DAPT Notch inhibitor Sigma Aldrich II
Fugene Transfection reagent Promega I, II
Turbofect Transfection reagent Thermo FisherScientific I, II, III
Lipofectamin
e Transfection reagent Invitrogen II
rEGF recombinant human EGF R&D Systems III
rFGF recombinant human basic FGF R&D Systems III
DABCO antifading reagent Sigma Aldrich I, II, III
Matrigel Matrix used for 2D and 3Dinvasion assays
BD Biosciences and
Corning I, III
Biotin used for biotinylation of all cellsurface proteins Pierce Biotechnology I
D-luciferase substrate for bioluminescenceimaging Regis Technology III
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3. Antibodies	
The following antibodies were used. The antibodies target human proteins unless stated
otherwise.
Name Source Manufacturer Articles used in
beta-tubulin rabbit Santa Cruz Biotechnology I, II
BrdU mouse Santa Cruz Biotechnology I
CD133 mouse Miltenyi Biotech III
Clathrin mouse Thermo Scientific II
GAPDH mouse Sigma Aldrich II
HA-11 mouse Covance I, II, III
HA-tag rabbit Cell Signaling III
HA-tag rat Roche III
ITGB4 chicken Sigma-Aldrich I
Jagged1 (C-20) goat Santa Cruz Biotechnology II, III
lamin A/C rabbit Novus Bio III
mouse CD31 rat BD Pharmingen III
Nestin rabbit Millipore III
Notc2 ICD rabbit Millipore II, III
Notch2 (25–255) rabbit Santa Cruz Biotechnology II, III
Notch2 cleaved
(D1733) rabbit Immunoway III
NTN1 mouse Enzo Biosciences II
NTN1 chicken Neuromics III
NTN4 goat R&D Systems I
Phalloidin Amanitaphalloides Sigma Aldrich II
phospho ERK 1/2 rabbit Cell Signaling I
phospho mTOR rabbit Cell Signaling I
phospho-AKT rabbit Cell Signaling I
4. Vectors and expression constructs 
Full-length NTN1 and NTN4 were cloned into pLVX-Puro expression vector. In addition, three
fragments of NTN1 and five fragments of NTN4 were cloned into pLVX-Puro vector. Since the
fragments were lacking the signal sequence of full-length proteins, CD33 signal sequence
was inserted into the 5′ end of the coding region of each construct. In addition, HA and Flag
tags were inserted into the C-terminal end of the proteins. All constructs are presented as a
table below.
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Name Protein coded Tags Plasmid Reference
NTN1 Full-length NTN1 none pLVX-Puro II, III
NTN1FH Full-length NTN1 Flag and HAtagged pLVX-Puro II, III
NTN(I)FH Amino acids 1-283 ofNTN1
Flag and HA
tagged pLVX-Puro II, III
NTN1(II)FH Amino acids 282-486 ofNTN1
Flag and HA
tagged pLVX-Puro II, III
NTN1(III)FH Amino acids 485-604 ofNTN1
Flag and HA
tagged pLVX-Puro II, III
NTN4 Full-length NTN4 none pLVX-Puro /pCDNA3 I
NTN4HF Full-length NTN4 Flag and HAtagged
pLVX-Puro /
pCDNA3 I
Fragment 1 Amino acid 1-261 of NTN4 Flag and HAtagged
pLVX-Puro /
pCDNA3 I
Fragment 2 Amino acid 261-445 ofNTN4
Flag and HA
tagged
pLVX-Puro /
pCDNA3 I
Fragment 3 Amino acid 261-516 ofNTN4
Flag and HA
tagged
pLVX-Puro /
pCDNA3 I
Fragment 4 Amino acid 445-628 ofNTN4
Flag and HA
tagged
pLVX-Puro /
pCDNA3 I
Fragment 5 Amino acid 516-628 ofNTN4
Flag and HA
tagged
pLVX-Puro /
pCDNA3 I
5. Lentivirus mediated manipulation of gene expression (I, II, III) 
Lentiviruses were produced in 293FT cells. The producer cells were transfected with lentiviral
packaging and envelope plasmids (pCMVdr8.74 and pMD2-VSVG; Addgene, Cambridge, MA)
together with the intended expression construct. 48 hours later the virus containing
supernatants were collected and virus titer determined. The target cells were then
transduced with the lentivirus supernatant and infected for 24 hours. For stable expression,
cells were selected with culture medium containing 5μg/ml puromycine. The expression of
selected gene was also ensured with QPCR and immunofluorescence.
For the overexpression of indicated genes an empty pLVX-Puro was used as infection control.
In the case of gene silencing, five shRNAs targeting the silenced genes were tested. The
shRNAs were obtained from RNAi Consortium through Open Biosystems. A nontargeting
scrambled shRNA construct was used as infection control.
6. Total RNA extraction, reverse transcription, and real-time 
quantitative-PCR (I, II, III) 
Total cellular RNA was purified using NucleoSpin® RNA II kit (Macherey-Nagel). Reverse
transcription was carried out using iScript cDNA Synthesis Kit (Bio-Rad). The relative amount
of mRNA of the indicated genes was measured with quantitative real time PCR using TaqMan
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Assays-on-Demand gene expression products (Applied Biosystems, Foster City, CA), and iQ
Supermix (Bio-Rad). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an
internal control for each sample. PCR was run using CFX96 machinery (Bio-Rad) and the
relative expression levels were quantified with ΔΔCT method with Bio-Rad CFX Manager
software.
7. In vitro cell proliferation assays (I, III) 
Cell proliferation was measured with bromodeoxyuridine assay (I) and EdU assay (II). In
bromodeoxyuridine assay cells were cultured on a 96-well plate (PerkinElmer, Waltham,MA).
Subsequently, the medium was replaced to medium containing 5-bromo-2-deoxyuridine
(BrdU) and incubated for 70 (serum containing) or 120 minutes (serum starvation). After
incubation, the BrdU labeling medium was removed, and the cells were washed with
phosphate-buffered saline (PBS) twice. The cells were then fixed with 70% ethanol
containing glycine at −20°C for 30 minutes. After washing with PBS, the cells were incubated
in 2 M HCl at room temperature for 60 minutes. Subsequently, the cells were rinsed and
treated with PBS containing 3% bovine serum albumin (BSA) at room temperature for 30
minutes and incubated with anti-BrdU antibodies. The primary antibody was detected by
A594  Alexa  Fluor  secondary  antibodies  (Invitrogen).  After  Hoechst  staining  at  4°C  for  15
minutes, cells were washed again. Finally, the images were captured and quantified by using
ArrayScan 4.5 high-content-screening system (Cellomics, Pittsburg, PA).
In the EdU assay the Click-IT EdU Imaging Kit (Life Technologies) and the standard protocol
of the manufacturer was used. In short, U87MG or U373MG cells were treated with 10 μM
of EdU for 60 min prior to fixation. Cells were stained using Click-IT EdU Imaging Kit with
AlexaFluor-594 conjugate (Thermo Scientic). The nuclei were visualized with 5 μg/ml of
Hoechst 44432 (Invitrogen). The proliferation rate was determined by dividing the total cell
number with EdU labeled cell number using ANIMA software (Rantanen et al., 2014).
8. 2D cell motility assays (I, II) 
Two types of 2D motility assays were utilized: scratch induced wound closure assay and
Matrigel invasion assay.
In the scratch induced wound closure assay, cells were cultured under normal conditions on
a 24-well plate until 90% confluency. A linear wound was scratched into the middle of each
well using micropipette tip. Detached cells were removed by washing with PBS. Cell culture
medium  containing  0,5%  serum  was  added  to  the  well.   The  migration  of  the  cells  was
monitored with Axiovert 200 inverted epifluorescence microscope. The migration rate was
assessed by analyzing the wound width at 0 and 8 hours timepoints using ImageJ software.
For the Matrigel invasion assays cell culture inserts with 8μm pore size (Becton Dickinson)
were coated with Matrigel (BD Biosciences) and dried.  20 000 cells were seeded on top of
the coated insert in a serum free DMEM. Serum containing DMEM was administered to the
lower chamber. Cells were allowed to invade for 7 hours in a cell culture incubator.  Next,
the cells were fixed with 40% MeOH, 10% CH3COOH and stained with Coomassie Brilliant
Blue. Cells that had not migrated through the inserts were removed. The inserts were imaged
with Axiovert 200 microscope (Zeiss) and the area covered by invaded cells was measured
with Image J software.
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9. Cell survival assay (I) 
Cells were cultured on glass coverslips overnight followed with 72 hour serum starvation.
Next, the coverslips were washed with PBS and fixed with 4% paraformaldehyde (PFA) in PBS
for 20 minutes. Apoptotic cells were detected using In Situ Cell Death Detection Kit (Roche,
Switzerland) according to the manufacturer's instructions. Finally, the coverslips were
mounted with VECTASHIELD antifading reagent (Vector Laboratories, Burlingame, CA) which
included 4′,6-diamidino-2-phenylindole for nuclei staining. The images were captured using
the 20x objective of the Axioplan microscope (Carl Zeiss, Inc, Thornwood, NY), acquired with
AxioCamHRc camera (Carl Zeiss) and AxioVision3.1 software (Carl Zeiss).
10. Immunofluorescence analysis of cells (I, II) 
Cells were grown on class coverslips and indicated treatments were applied. The cells were
fixed with 4% PFA and permeabilised with 0,1% Tx100 in TBS. Then cells were incubated with
3% BSA or 5% non-fat milk in PBS to prevent the non-specific binding of antibodies. Primary
antibodies were diluted to the blocking buffer and incubated on the cells for 60 minutes.
After incubation the excess primary antibodies were removed by washing with PBS. The cells
were then incubated 30 min with fluorescent labelled Alexa secondary antibodies
(Invitrogen) which were diluted to the blocking buffer. Subsequently, nuclei were visualized
with Hoechst 33342 (Sigma Aldrich). Excess antibodies were again washed away with PBS
and lastly with water. TH coverslips were mounted on microscopic slides with Mowiol
mounting medium (Calbiochem) supplemented with 6mg/ml DABCO (Sigma Aldrich). The
cells were analyzed under Zeiss Axioplan 2 or Zeiss AxioImager.Z2 upright epifluorescence
microscopes. Depending on the microscope used the images were acquired using Zeiss
digital AxioCam grayscale camera and AxioVision 4.6 software or Hamamatsu Orca Flash 4.0
LT, 4 megapixel monochrome sCMOS camera and Zeiss Zen 2 pro software, respectively.
Alternatively,  Zeiss  LSM  510  Meta  or  LSM  880  laser  scanning  confocal  microscopes  were
utilized for capturing micrographs.
11. SDS-PAGE and immunoblot analysis (I, II, III) 
Cells were harvested by lysing with Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5%
sodium deoxycholate, 0.1% SDS and complete protease inhibitors (Roche). Nuclei were
removed by centrifugation. The proteins were electrophoretically separated in 4%-20%
gradient Tris-HCl polyacrylamide gels (Lonza and Bio-Rad). The proteins were then
transferred onto nitrocellulose membranes (Bio-Rad) using semi-dry method and Trans-Blot
Turbo apparatus (Bio-Rad). The efficiency of the transfer was confirmed with Ponceau
staining of the membrane. The membrane was then incubated with 3% BSA or 5% non-fat
milk and 0,05% Tween-20 in TBS. Primary antibodies were diluted into the blocking buffer,
administered to the membrane and incubated at 4°C overnight. Membrane was washed
several times. Horseradish peroxidase conjugated secondary antibodies (GE Healthcare)
were diluted to the blocking buffer and incubated with the membrane for 60 min at room
temperature. Finally, the filter was washed and the immunoreactive proteins were visualized
by  ECL-reagent  (GE  Healthcare)  and  exposing  to  X-ray  film  (Fujifilm).  The  films  were
developed using Kodak X-OMAT 2000 equipment (Kodak).
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Phosphospecific Western blot analysis was performed according to the manufacturer's
instructions (Cell Signaling Technology, Danvers, MA).
Quantification of western blots that were processed as described above, was performed with
ImageJ software from the scanned X-ray film images. Alternatively a methods based on
fluorescently labelled secondary antibodies was utilized.  After transferring the proteins to
nitrocellulose membranes, immunoblotting was performed according to the protocol
suggested by Li-Cor Biosciences. The membrane was scanned with the Odyssey Infrared
Imaging System (Li-Cor Biosciences). Intensities of the bands were analyzed using Odyssey
2.1 software (Li-Cor Biosciences).
12. Identification of binding partners of netrins (I, II) 
Cells expressing tagged NTN1 fragments were lysed with lysis buffer containing Tris-HCl pH
7.5, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS and complete
protease inhibitors (Roche). The cell lysates were incubated with FLAG–Sepharose on a
shaker at +4°C for 12 hours. Next, the Sepharose particles were collected by centrifugation
and washed with the lysis buffer. The proteins bound to the FLAG-Sepharose were detached
by incubation with 150 ng/μl FLAG peptide (Sigma Aldrich) at +4°C for 2 hours and
subsequently incubated with anti-HA Sepharose in an end-over-end rotating shaker for 1
hour. After incubation the Sepharose particles were washed with the lysis buffer. Finally, the
Sepharose-bound proteins were eluted by incubating the particles with non-reducing
Laemmli sample buffer at 100°C for 5 minutes. The eluted proteins were then separated by
SDS-PAGE (10–20% gradient gels) and visualized by Proteo Silver silver staining kit (Sigma
Aldrich) according to manufacturer’s protocol. For the identification, proteins were in-gel
digested with trypsin and the resulting peptides were identified by liquid chromatography–
tandem mass spectrometry analysis as previously described (Ohman et al., 2014).
13.  Monitoring the Notch signaling activation (II) 
Notch signaling activation was monitored using luciferase reporter assays. A Notch response
element containing plasmid TP1-luc(981-6) and a Notch2-intracellular-domain-encoding
plasmid, pEF-BOSneoSE-mNotch2 RAMIC, were acquired from RIKEN BioResource Center
DNA (Kato et al., 1996; Kurooka et al., 1998). pRL-TK Renilla luciferase vector (Promega) was
used as a transfection control in luciferase assays.
A plasmid containing the Notch response element controlling the transcription of the
luciferase gene (TPI-luc) was co-transfected by Fugene 6 transfection to target cells together
with constitutive expression of Renilla luciferase (pRL-TK) and pCR 3.1 empty vector
(Invitrogen) (Kurooka et al., 1998). In the positive control pCR 3.1 vector was replaced with
the intracellular domain of Notch2 containing pEF-BOSneoSE-mNotch2 RAMIC (Kato et al.,
1996). Transfection was done according to manufacturer’s instructions. After 48 hours the
cell lysates were collected and luciferase activity was measured with the Dual Luciferase
Assay Kit (Promega) using a Digene DCR-1 luminometer.
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14.  Biotinylation of the cell surface proteins (II) 
First cells were washed with cold phosphate-buffered saline. EZ-Link Sulfo-NHS-LC-LC-Biotin
(0.5  mg/ml)  in  PBS (Pierce Biotechnology)  was administered to  cells  and allowed to react
with the cell surface proteins on ice for 1 hour. Excess biotin was removed by washing the
cells with 150 mM glycine in Tris-buffered saline, pH 7.5. Next, the cells were lysed with 50
mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate (DOC), 0.1%
SDS supplemented with Complete protease inhibitor (Roche). The nuclei were removed from
lysates by centrifugation and the cell lysates were preabsorbed with protein-G–Sepharose
(GE healthcare) at +4°C for 1 hour. Next, the lysates were then incubated with either anti-
Notch2 extracellular or anti-Jagged1 antibodies at +4°C for 1 hour. The antibodies together
with their binding proteins were precipitated with protein-G–Sepharose. Subsequently, the
Sepharose particles were washed and the bound proteins were eluted with Laemmli sample
buffer by boiling at +100°C for 5 minutes. The eluted, biotinylated proteins were analyzed
with SDS-PAGE and immunoblotting with horseradish peroxidase conjugated streptavidin.
The biotinylated Notch2 or Jagged1 proteins were identified based on their expected
molecular weight.
15. Tissue microarray analysis (TMA) (III) 
All experiments involving the use of human tumor tissue was authorized by the Operative
Division of Ethical Committee of Helsinki University Hospital (license number
276/13/03/02/2013) and The National Supervisory Authority for Welfare and Health (license
number 95/06.01.03.01/2014). NTN1 expression was analyzed in two paraffin embedded
tissue microarrays: an array containing 103 low grade glioma samples previously described
in (Tynninen et al., 2004) and an array consisting of 40 GBMs. 5 μm thick tumor sections were
cut on SuperFrost+ slides (Menzel-Gläser),  deparaffinized in xylene and rehydrated in a
decreasing ethanol gradient series. The sections were incubated in 3% hydrogen peroxide
for 30 minutes to quench the endogenous peroxidase activity. Subsequently, the epitope
was retrieved using heat induced epitope retrieval in sodium citrate buffer (10 mmol/L, pH
6.0). Next, the sections were incubated with NTN1 overnight in +4 degrees. Excess primary
antibody was washed away and secondary antibodies from ImmPress (Vector laboratories)
staining kit was added according to manufacturer’s instruction.  Finally, the NTN1 on tissues
was detected with a DAB Peroxidase Substrate Kit (Vector Laboratories) 15 minutes at room
temperature and counterstained using hematoxylin. Kidney tissue was used as positive
control. The NTN1 expression was evaluated and scored by experienced pathologist. Samples
were scored either NTN1 positive or negative.
16.  Tissue immunofluorescence analysis (III) 
In addition, we collected fresh glioblastoma tumor biopsies directly from the surgery. The
tissue was washed with DMEM/F12, embedded into OCT compound (Sakura Biotech) in a
cryomold and fresh frozen using liquid nitrogen. After freezing the tissueblock was stored in
-80oC. For immunofluorescence staining 7 μm thick sections were cut with Cryotome (Sakura
Biotech) and transferred onto microscope slides for staining. The slides were either stained
directly or stored in -20oC.
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For immunofluorescence staining, 7 μm thick sections were prepared and transferred onto
SuperFrost+ slides (Menzel-Gläser). Slides were either processed immediately or stored in -
20oC.
17.  In vivo xenograft studies (III) 
All experiments involving mice were approved by the National Animal Experiment Board
(license number ESAVI/6285/04.10.07/2014). For the xenograft studies we first created
stably luciferase expressing U87MG and U373MG cells. These cells were then further
transduced to produce either NTN1FH or NTN1(II)FH. The cells were implanted into the brain
of BALB/C NU/NU athymic mice as described earlier (Lee et  al., 2012; Ozawa and James,
2010). Five mice per cell-line were used. Intracranial implantation of the cells was performed
as previously published. Shortly, 150 000 cells in 5μl of PBS were intracranially injected. The
injection site was positioned 2 mm right and 1 mm anterior to the bregma suture and 2,5mm
in depth. The tumor growth was followed with bioluminescence imaging. 3mg of D-Luciferin
(Regis Technologies) in PBS was administered intraperitoneally to each mouse and allowed
to circulate for 15 min. The photons emitted by the tumors were imaged using Perkin-Elmer
IVIS 100 imaging system. The mice were sacrificed 21 days after U87MG implantations and
52  days  after  U373MG  implantation.   Their  brain  was  collected  fixed  with  4%
paraformaldehyde in PBS for 30 min. The tissue was then washed with PBS and incubated
with 30% sucrose 24 hours. After that the tissue was embedded into OCT compound (Sakura
Bioteh) in a cryomold (Sakura Biotech) and frozen using liquid nitrogen. The frozen tissue
blocks were then stored in -80oC.
18.  3D ex vivo GBM tissue culture (III) 
Fresh GBM tissue biopsies were washed with PBS and embedded into 50μl of Matrigel. The
Matrigel was allowed to polymerize for 30 min in +37oC. DMEM/F12 cell culture medium
supplemented with 100 IU/ml penicillin, 50 mg/ml streptomycin, B27 supplement, EGF
20ng/ml, FGF 20ng/ml was added on top of Matrigel drops. Tissue pieces were allowed to
grow and invade for 7 days. Next, the Matrigel drops were transferred into cryomolds filled
with OCT compound (Sakura Biotech) and fresh frozen with liquid nitrogen. 7μm thick
sections were cut onto Superfrost slides. The tissue sections were then subjected to tissue
immunofluorescence analysis.
19.  Establishing primary GBM cell lines (III) 
Primary GBM cultures were established according to a previously published protocol
(Hasselbach et al., 2014b). Briefly, fresh GBM tissue biopsies were minced and cells detached
by with trypsin and vigorous mixing. Trypsin was inhibited and cells collected by
centrifugation. The number of viable cells was determined with Trypan blue (Bio Rad). The
cells were diluted into density of 50 000 cells/ml into DMEM/F12 cell culture medium
supplemented with 100 IU/ml penicillin, 50 mg/ml streptomycin, B27 supplement, EGF
20ng/ml,  FGF 20ng/ml.  The medium was changed twice a  week and cells  passaged every
second week.
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20.  Co-culture of GSCs and U251MG cells in 3D Matrigel (III) 
First, a GFP encoding pLenti CMV GFP Puro plasmid (Addgene) was lentivirally transduced
into stably NTN1FH and NTN1(II)FH expressing U251MG cells. The stable GFP expression was
ensured with flow cytometry based cell sorting. Next, the NTN1 and GFP expressing U251MG
cells were mixed with primary GBM cells and allowed to form spheroids in non-adherent
agarose coated U-bottom plates. Five spheroids were then mixed with 50μl Matrigel and
plated on cell culture plates. The Matrigel was allowed to polymerize for 30 minutes and cell
culture medium was added to the wells. The spheroids was imaged under Cell-IQ imaging
system (Chip Man Tehcnologies) for 24 hours. The growth of the spheroids was analysed by
measuring the area of the cells in different timepoints using the Cell IQ image analysis
software (Chip Man Tehcnologies). The spheroids were fixed with 4% PFA 30min,
permeabilised with 0,3% Tx100 PBS and subjected to immunofluorescence staining.
21. Statistical analysis (I, II, III) 
Results are represent as the mean of at least three independent repeats. Error bars represent
the standard deviation or standard error of mean. Statistical significance was analyzed with
non-parametric Mann–Whitney U-test for independent samples.
22.  Bioinformatics analysis (I, II) 
Exon array data of 425 primary GBM samples and 10 normal brain tissues were obtained
from The Cancer Genome Atlas (TCGA) (Cancer Genome Atlas Research Network, 2008).
Preprocessing was performed at the gene expression level using the Multiple Exon Array
Preprocessing (MEAP) algorithm (Chen et  al., 2011). Subsequent data analyses were
performed using the Anduril framework (Ovaska et  al., 2010). Candidate pathways were
investigated using the Moksiskaan database to determine comprehensive signaling pathway
networks from canonical pathways (Laakso and Hautaniemi, 2010). To analyze the survival
of patients, 393 samples that had survival end time in the TCGA GBM repository were used.
Fold change (FC) values were calculated by taking the median and used in grouping for
Kaplan-Meier survival analysis, where patients were divided into groups denoted by “-1”
(underexpression, FC < 0.5), “1” (overexpression, FC > 3), and “0” (stable expression). Survival
P values were calculated with the log rank test, and the threshold used in our analysis was P
< .05.
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RESULTS
1. NTN4 promotes GBM cell proliferation and motility in a 
concentration dependent manner (I) 
Previously high expression of NTN4 had been shown in normal human astrocytes (Staquicini
et al., 2009). To investigate the effects of NTN4 in GBM cells we utilized three glioma cell-
lines: U87MG, U251MG and U373MG. Interestingly, all studied glioma cell lines did express
NTN4 but less than normal astrocytes. To characterize the effects of NTN4 on the GBM cells
its expression was silenced using lentivirus mediated shRNA delivery. The silencing of NTN4
led to the decrease of cell proliferation in BrDU incorporation assay, decreased cell migration
in wound closure assay and increased apoptotic labeling in TUNEL assay. Furthermore,
exogenous addition of recombinant NTN4 increased cell proliferation and migration.
However, the additive effect was concentration dependent: addition of 50ng/ml and
200ng/ml increased the proliferation and migration while addition of 5000ng/ml did not
affect or even suppressed proliferation and migration. Similar findings were observed with
U373MG whereas in U87MG cells NTN4 induced effects were limited to cell proliferation.
2. NTN4 stimulates GBM cell proliferation via ITGB4 dependent 
AKT-mTOR phosphorylation (I) 
Tandem affinity purification and mass spectrometry screen demonstrated that NTN4 interact
with ITGB4. This observation was validated using immunoprecipitation and
immunofluorescence analyses. Interestingly, examination of the TCGA database revealed
that the expression levels of NTN4 and ITGB4 are opposite in GBM tissue: NTN4 was
downregulated whereas the expression levels of ITGB4 were upregulated. However,
decrease in NTN4 and increase in ITGB4 were both associated with poor patient survival.
AKT, mTOR and insulin receptor substrates are mediators of ITGB4 signaling (Nikolopoulos
et al., 2004; Shaw, 2001). In our screen, insulin receptor substrates were also identified to
interact with NTN4. Previously, it has been shown that NTN is connected to AKT signaling
pathway in tumor cells (Nacht et al., 2009). In addition, mTOR signaling has been previously
linked to cell proliferation (Shaw and Cantley, 2006). Further investigation revealed that
NTN4 silencing decreased phosphorylation of AKT, mTOR and ERK1/2 whereas exogenous
addition of 0-50ng/ml recombinant NTN4 increased it. Silencing of ITGB4 abolished this
effect suggesting that it is an essential mediator of NTN4 induced AKT-mTOR
phosphorylation.
3. NTN1 promotes GBM cell invasiveness in vitro and in vivo (II, 
III) 
We then went on to characterize the expression levels of NTN1 in three GBM cell lines:
U87MG, U251MG and U373MG using quantitative western blotting and qRT-PCR.
Interestingly, when compared to human normal astrocytes the expression of NTN1 was
upregulated in invasive GBM cell lines U251 and U373MG whereas in solid tumor forming
U87MG the expression was downregulated.
Intrigued by these findings we hypothesized that NTN1 is a regulator of GBM invasion. We
first tested this on cell-lines in vitro. In a 2D Matrigel invasion assay NTN1 overexpression
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increased U251MG cell invasion whereas lentivirus mediated shRNA knock-down reduced it.
The reduction was observed in a manner corresponding to the efficiency of the silencing.
Complete silencing led to the apoptotic death of the cells (unpublished data). The role of
NTN1 in the GBM invasiveness was further deciphered in an in vivo xenograft model. First,
NTN1 overexpressing or wildtype U87MG cells were orthotopically xenografted into nude
mice. The cells were expressing firefly luciferase to allow tumor growth monitoring by
bioluminescence imaging. NTN1 expression resulted in more widely spread tumor and
stronger bioluminescent signal.
After sacrificing the mice the growth of the tumors was assessed on tissue sections of the
brain. Consistently with the bioluminescence imaging tumors formed by NTN1
overexpressing cells were larger and more invasive. The invasive fronts of the NTN1
expressing tumor were less well-defined and single tumor cells had started to spread to the
brain parenchyma along the blood vasculature. These findings confirm the role of NTN1 as
invasion promoting factor in GBM.
4. NTN1 is a multifunctional protein which associates with 
several proteins and signaling pathways (II) 
The proteins interacting with NTN1 were screened using tandem affinity chromatography
and identified with mass spectrometry. For the purification, all NTN1 domains (N-terminal
domain = NTN(I)FH; central domain = NTN1(II)FH; C-terminal-domain = NTN1(III)FH) were
expressed separately in U251MG cells and tagged with FLAG and HA tags for the pull down.
The different domains served as internal controls for each other and also provided
information on the roles of the different domains.
Our screen was validated by the identification of two known NTN1 receptors ITGA3B1 and
ITGB4 (Yebra et al., 2003). The pathways that NTN1 was associated with were identified using
automated pathway analysis that is based on Kyoto Encyclopedia of Genes and Genomes. It
revealed that NTN1 associated with various cell signaling pathways including ECM-receptor
interaction, insulin signaling and TGF-beta signaling pathway. However, out of the identified
pathways the most prominent candidate pathway was Notch signaling pathway. NTN1(I)FH
interacted with Notch2 and Notch3 receptors, NTN1(II)FH with Notch1 and Notch2 receptors
and NTN1(III)FH with Notch2 receptors. NTN1(II)FH also interacted with known the Notch
ligand Jagged1.
Protease mediated cleavage of the Notch receptor and the endocytosis of the intracellular
domain of the receptor are important parts in the activation of the Notch signaling (reviewed
in Parks et al., 2000; Pratt et al., 2011). Interestingly, different NTN1 domains interacted with
several proteins which may be related to the Notch signaling activation. NTN1(I)FH
interacted with several endocytosis related proteins, NTN1(II)FH interacted with E3 ligases
and NTN1(II)FH with multiple proteases. These results suggest that the domains may
independently modulate the Notch signaling.
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5. NTN1 can activate Notch signaling and induce subsequent cell 
invasion by binding to the Notch-Jagged complex (II) 
The binding of NTN1 and Notch signaling components was validated by immunoprecipitation
and western blotting. Indeed all the domains could pull-down Notch2 and Jagged1 from
U251MG cell lysate. However, the pull-down was most efficient with full-length NTN1 and
NTN1(II)FH. The interaction was further analyzed using immunofluorescence microscopy.
U251MG cells were treated with NTN1FH containing medium either at 37°C or at +4°C. When
the treatment was performed at +4°C NTN1FH colocalized strongly with Jagged1 on cell-cell
contacts. At +37°C, NTN1FH and Jagged1 colocalized in vesicle-like structures suggesting that
they are endocytosed together. On the other hand, NTN1FH colocalized with Notch2 on cell
surface in both temperatures.
The ability of NTN1 to modulate Notch signaling was investigated using a Notch reporter
assay. A construct where Notch response element controlled luciferase coding gene was
transiently transfected into either NTN1 overexpressing or NTN1 silenced U251MG cells.
NTN1 upregulation induced over 2-fold increase in Notch activation in comparison to
wildtype U251MG cells. Consistently, NTN1 silencing decreased Notch signaling significantly.
Furthermore, we also examined how Notch signaling inhibition affects the invasiveness of
GBM cells. We utilized DAPT, a compound that prevents the γ-secretase mediated cleavage
of Notch receptor which is essential for the activation of the signaling. U251MG cells were
used in Matrigel invasion assay with or without DAPT. Upon DAPT treatment the invasive
capability of the cells was markedly reduced.
Taken together these results suggest that NTN1 can bind to the signaling complex of Notch2
and Jagged1 and activate the Notch signaling. NTN1 is endocytosed together with Jagged1
plausibly after the cleavage of the Notch receptor. Furthermore, inhibition of Notch signaling
with DAPT inhibited cell invasion similarly to NTN1 suggesting that it is mediating NTN1
effects.
6. The expression of NTN1 in human glioma biopsies is 
associated with poor patient prognosis (II, III) 
The expression of NTN1 in human gliomas was analyzed both on gene and protein expression
levels. TCGA exon array datasets revealed that the expression of NTN1 was markedly
upregulated in GBM samples compared to normal brain.  Next, the NTN1 expression was
assessed in a tissue microarray of 136 tissue samples which included astrocytoma, anaplastic
astrocytoma, oligodendroglioma, oligoastrocytoma and glioblastoma tumors (Sihto et  al.,
2007; Tynninen et al., 2004). NTN1 was expressed in all glioma subtypes. Within all the tissue
samples 40.4% of the tumors were NTN1 positive. NTN1 was strongly associated with
astrocytic tumors. Within astrocytomas 77.8%, within anaplastic astrocytomas 62.5% and
within GBMs 77.1% of the tumors were NTN1 positive whereas within oligodendrogliomas
and oligoastrocytomas only 26.7% and 36.8%, respectively, were NTN1 positive. No
association with gender or age at the time of diagnosis was observed.
Furthermore, we investigated how NTN1 expression in gliomas was related to the survival of
the patients and performed Kaplan-Meier survival analysis. Both glioma-specific overall and
recurrence-free survival times were analyzed. Interestingly, NTN1 positivity was associated
with poor glioma specific survival (hazard ratio [HR] = 1.73, 95% confidence interval [95% CI]
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= 1.11 to 2.71; p=0.015) and shorter recurrence-free survival time (HR = 1.62, 95% CI = 1.04
to 2.53; p<0.001) (Fig. 1B). However, when astrocytomas and oligodendroglial tumors were
analyzed separately NTN1 expression was not significantly associated with patient survival.
7. NTN1 locates to GSC-rich tumor areas and to the stalk area of 
GSC led invasive structures (III) 
Next, we analyzed the localization of NTN1 in glioma tissue. In all glioma subtypes NTN1 was
enriched to areas surrounding the necrotic tumor core and especially to pseudopalisade
structures that contain actively migrating cells (Brat et al., 2004a) in GBM samples. Also the
abnormal glomerular vessels of GBM tumors were positive for NTN1.
The hypoxic and perivascular GBM tumor areas where NTN1 was located are known to be
rich in GSCs (Bar et al., 2010; Bar et al., 2010; Calabrese et al., 2007; Heddleston et al., 2009).
While we were deciphering the expression of NTN1 in the glioma TMAs we also observed
that NTN1 and nestin expressions correlated. Previously, nestin has been connected to the
stemness of the GBM cells and to the poor prognosis of glioma patients (Strojnik et al., 2007;
Zhang et al., 2008). In addition, Notch signaling has been observed to promote the stemness
of  the  GBM  cells  (Chen et al., 2010; Fan et  al., 2010; Hu et  al., 2011). Therefore, we
hypothesized that NTN1 affects the GSCs via Notch signaling. To explore this further we
examined whether NTN1 co-localizes with known GSC markers nestin and CD133 in fresh
frozen GBM tissue. Interestingly, we did not observe co-localization of NTN1 in same cells
with either of these markers. Instead, NTN1 localized to neighboring cells of nestin
expressing cells. Similar localization was observed with CD133. In the GBM tissues there were
areas with CD133 positive cells surrounded by NTN1 positive cells. Next, we investigated the
co-localization  of  NTN1  and  Notch2  receptor  or  Jagged1  ligand  on  the  GBM  tissue.  We
observed that NTN1 and Jagged1 co-localized on the same cells in a manner similar to what
we observed in in vitro cultured GBM cells. In contrast, NTN1 and Notch2 were not co-
localized in same tumor cells. Instead, we observed that Notch2 and NTN1 were expressed
in neighboring cells and were co-localized within their cell-cell contacts.
We also analyzed the NTN1 and nestin localization in the U87MG xenografts. Expression of
CD133 could not be studied because the U87GM cells do not express it. We stained the
NTN1FH  tumor  sections  for  nestin  and  HA  to  localize  NTN1  positive  cells  in  the  tumors.
Unexpectedly, we detected that the invasive edge was strongly nestin positive in NTN1
overexpressing tumors but not in control tumors. Furthermore, we observed that the
invasive structures consistently showed an assembly where the nestin positive cells were on
the leading edge whereas NTN1 positive cells were following them. We also observed similar
pattern with Notch2 staining. Again, the NTN1 positive cells were in the stalk area of the
invasive sprouts whereas Notch2 positive cells were in the invasive front.
Because these results link NTN1 strongly to GBM invasiveness and stemness we were
interested in examining its localization in the invasive cells of human GBM too. However, the
surgical human GBM biopsies represent primarily the tumor core because the single invasive
cells are impossible to remove upon surgery. To mimic the invasive front of human GBM we
established ex vivo human GBM cultures. We implanted freshly collected GBM biopsies in
3D Matrigel and allowed the cells to grow and migrate for 7 days. The Matrigel plugs were
then fresh frozen and sectioned. Immunofluorescence staining of the sections revealed
similar pattern that was observed with the xenografts. The front of the invasive structures
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was positive for Notch2 and for nestin suggesting that these cells are more stem-like than
the cells in tumor core. Again, NTN1 positive cells remained at the stalk area of the invasive
sprouts. These findings are consistent with the observations of the U87MG xenograft model
where the leading cells of the invasive structures were nestin and Notch positive whereas
NTN1 positive cells remained in the stalk area of the structures.
8. NTN1 increases the number of GSCs in the cell population and 
stimulates their motility (III) 
To analyze how NTN1 affects the GSCs, we cultured both wild type and NTN1 overexpressing
U251MG GBM cells under conditions that favor neural stem cell proliferation (Wakimoto et
al., 2012). Interestingly, NTN1 overexpression led to 16-fold higher neurosphere formation
compared to wild-type cells. These neurospheres also expressed stemness markers Sox2,
nestin and integrin alpha6 more than normal U251MG cells. This suggests that the initial
NTN1 overexpressing cell population contained a higher number of GSCs and that NTN1 plays
a role in their maintenance.
Next, we investigated how NTN1 affects the motility of the GSCs and used 2D and 3D invasion
assays. The U251MG GSCs were either plated as single cells on top of 2D Matrigel or the
neurospheres as such were implanted into 3D Matrigel. 50ng/ml of recombinant NTN1
(rNTN1) was utilized as attractant in the assays. In both assays the addition of rNTN1
enhanced the motility of the cells: they either invaded through the Boyden chamber more
effectively or the neurospheres spread much faster upon rNTN1 addition. Furthermore, the
control spheroids remained more compact compared to rNTN1 treated, which spread more
diffusively. These results suggest that rNTN1 regulates the motility of GSCs.
9. NTN1(II)FH diminishes the activation Notch signaling by 
retaining Notch-Jagged1 signaling complex on cell surface 
(II) 
While we were validating the mass spectrometry results we observed that both the full-
length NTN1 and its central domain (NTN1(II)FH) bound to Notch2 and Jagged1 most
efficiently. Therefore, we included NTN1(II)FH into our further analysis too.
Immunofluorescence analysis revealed that NTN1(II)FH also co-localized with both Notch2
and Jagged1 on cell surface but it was not internalized with either of them. Surprisingly, its
effect to the Notch signaling pathway was opposite than the full-length NTN1: NTN1(II)FH
decreased the activation whereas NTN1 activated it. Furthermore, it modulated the
morphology of the cells towards a smaller and more rounded phenotype. Similar effect has
been observed upon Notch signaling inhibition with DAPT (Ingram et al., 2008). Because the
U251MG cells express NTN1 endogenously, our results suggest that NTN1(II)FH can
overcome the effects of the full-length protein.
We then analyzed whether the defect in Notch signaling was due to the altered cell surface
localization of either Notch2 or Jagged1. We biotinylated all cell surface proteins and
visualized the cell surface fraction of Notch and Jagged with immunoprecipitation and
immunoblotting. Both Notch2 and Jagged1 were similarly expressed on the surface of
wildtype U251MG cells or stably NTN1 or NTN1(II)FH expressing U251MG cells. Surprisingly,
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we observed that upon NTN1(II)FH expression Notch2 could more effectively
immunoprecipitate Jagged1 from the cell surface. Furthermore, the co-localization of Notch2
intracellular domain and clathrin on cell membrane was decreased. Because Notch
internalization which is required for the signaling activation occurs via clathrin mediated
endocytosis (Windler and Bilder, 2010) our findings suggest that NTN1(II)FH decreases the
signaling by retaining the Notch signaling complex on cell surface.
10. Inhibition of NTN1 signaling with NTN1(II)FH reduces GBM 
invasiveness via decreasing the motility of GSCs (II, III) 
Since NTN1(II)FH had the opposite effect on Notch signaling compared to full-length NTN1
we were interested in testing how it affects cell invasiveness. We first studied this in vitro in
2D Matrigel invasion assay. As expected, the expression of NTN1(II)FH decreased the
invasiveness of U251MG cells. Next, the effects of the NTN1(II)FH were evaluated in vivo. We
performed intracranial xenografts in nude mice and used either wildtype, NTN1FH
expressing or NTN1(II)FH expressing U373MG cells. The U373MG cells were employed
because they endogenously express NTN1 and thus were a good model to study NTN1
inhibition. Again, the tumor growth was monitored using bioluminescence imaging. After 6
weeks we started to observe differences in the tumor growth between the groups. Both the
control tumors and NTN1FH tumors grew all around the mouse head area and also spread
along the spine of the mice whereas the growth of the NTN1(II)FH tumors was restricted to
the head area. When we measured the emitted photons only from the head area of the mice
we could not observe any significant difference between the groups. However, combining
the signal from the head and the spine of the mice revealed a significant decrease on the
photons within NTN1(II)FH group. These results suggest that NTN1(II)FH can antagonize the
effects of endogenously expressed NTN1.
Next, we wanted to analyze does NTN1(II)FH affect the motility of the GSCs. Freshly isolated
GBM cell-lines that are kept under the stem-like cell proliferation favoring culture conditions
are a better model for investigating glioma stem-like cells than long cultured cell (Ahmad  et
al., 2014; Wakimoto et  al., 2012). Therefore, we established primary GSC cultures from
surgical GBM biopsies, named GBM9 and GBM10, which were constantly cultured under
stem-like cell proliferation favoring conditions. Because GBM tumors are heterogeneous and
contain both GSCs and differentiated tumor cells we mixed the GBM9 or GBM10 cells with
NTN1 expressing and GFP labelled U251MG cells. The U251MG cells cultured under adherent
conditions mimicked the differentiated GBM cell population in the human tumors. These
mixture spheroids were then embedded into 3D Matrigel matrix.
We observed that once the GBM9 cells were mixed with control U251MG cells or NTN1FH
expressing U251MG cells (GBM9/U251MG and GBM9/U251MG-NTN1FH spheroids
respectively) the spheroids invaded diffusively and presented two types of sprouts: sprouts
where the GFP positive U251MG cells were leading and where GFP negative GBM9 cells
where leading. On the contrary, the GBM9 and U251-NTN1(II)FH spheroids
(GBM9/NTN1(II)FH) invaded in more compact manner and presented only GFP positive
sprouts. We quantified the sprouts and indeed in GBM9/U251 and in GBM9/U251-NTN1FH
spheroids both sprout types existed in equal proportions. In GBM9/U251MG-NTN1(II)FH
spheroids more than 80% of the sprouts were led by U251GM cells. Consistent results were
obtained with GBM10 and U251MG cell mixtures.
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Immunofluorescence staining with nestin and HA to recognize NTN1 confirmed that
GBM9/U251-NTN1FH spheroids presented similar GSC led sprout assembly than in the
xenograft and ex vivo models. In addition, the cells leading the invasion were positive for
cleaved-Notch suggesting activated Notch signaling. In contrast, the sprouts led by the nestin
positive and Notch-activated cells were lacking in the GBM9/U251-NTN1(II)FH spheroids.
Taken together these results suggest that NTN1 regulates the GBM invasiveness by
promoting the motility of the GSCs and the inhibition of the NTN1 signaling with NTN1(II)FH
peptide reduces the invasiveness of especially GBM stem-like cells.
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DISCUSSION
1. NTN4 regulates the proliferation of glioma cells via 
orchestrated actions of ITGB4 and UNC5B (I) 
NTN4 is a multifunctional protein that has been linked to many cancers. However, its role is
controversial since some reports have identified it as cancer promoter and others as a tumor
suppressor. Here we have investigated its effects and signaling in glioblastoma. We observed
that it modulates glioblastoma cell motility, survival and proliferation in a concentration
dependent manner: low concentration promoted these effects whereas high concentrations
inhibited them. Similarly NTN4 regulates adhesion, migration, proliferation and apoptosis of
endothelial cells in a concentration dependent manner (Larrieu-Lahargue et al., 2010; Lejmi
et al., 2008; Wilson et al., 2006). Furthermore, we observed that its expression is reduced
during glioma progression and that low NTN4 expression is correlated with poor patient
prognosis. Taken together, these findings provide evidence that NTN4 plays a dual function
in glioma progression and that its effects depend on a balance of its expression. These results
could also explain the previous contradicting results in other cancers.
To better understand how NTN4 regulates glioma cells we screened for pathways mediating
its effects. We discovered that ITGB4 binds to NTN4 and mediates the positive effects of
NTN4  on  glioblastoma  cell  proliferation.  Previously  ITGA2B1  and  ITGA3B1  have  been
recognized as NTN4 receptors (Maedler et  al., 2011). Furthermore, ITGB4 is expressed
strongly in astrocytes, and it is upregulated during glioma progression (Previtali et al., 1996).
Consistently, we observed that ITGB4 upregulation is associated with poor patient survival
in GBM.
Interestingly, suppression of NTN4 expression in ITGB4-silenced cells slightly increased cell
proliferation, and NTN4 overexpression led to decreased proliferation in ITGB4- silenced
glioblastoma cells. These results suggest that there are other mechanisms mediating the
negative effects of NTN4. Previously, UNC5B has been observed to mediate NTN4 induced
inhibitory functions of endothelial cells (Lejmi et al., 2008). Therefore, we analyzed whether
UNC5B could be the receptor mediating the negative effects also in GBM. Unlike NTN4 and
ITGB4 the expression of UNCB5 was not altered in GBM when compared to normal brain.
Silencing of UNC5B led to decreased proliferation of GBM cells. Addition of high
concentration of NTN4 did not further suppress the proliferation suggesting that UNC5B is
mediating this effect.
Our findings elucidate a complicated mechanism by which NTN4 regulates the proliferation
of GBM cells. When there is excess supply of NTN4 available it binds to UNC5B which then
suppresses cell proliferation. NTN4 also binds to ITGB4 that is expressed in low levels and
induces proliferation. This balance maintains the glial cell proliferation on a sufficient level
for normal growth. However, during tumor progression the expression level of ITGB4 gets
upregulated and NTN4 gets downregulated while the level of UNC5B remains unchanged.
The relatively low number of NTN4 proteins bind efficiently to ITGB4 due to its abundant
expression on cell surface. Since majority of the NTN4 binds to ITGB4 the UNC5B mediated
proliferation inhibition is lost and ITGB4 signaling upregulate GBM cell proliferation.
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2. NTN1 drives the GBM invasion and stemness via Notch 
signaling (II, III) 
Like NTN4 also NTN1 regulates several cancers. It acts as invasion promoting factor in
pancreatic, colorectal and hepatocytic cancer and in medulloblastoma (Akino et al., 2014;
Dumartin et al., 2010; Rodrigues et al., 2007; Yan et al., 2014). Interestingly, NTN1 has been
suggested to function also as a potential biomarker in both glioblastoma and
medulloblastoma (Akino et al., 2014; Ramesh et al.,  2011). In this thesis, we link NTN1 to
glioblastoma invasion and stemness. The expression of NTN1 is high in glioblastoma derived
cell-lines that show infiltrative growth in vivo but not in less malignant cells. In a TMA screen
of various glioma biopsies, NTN1 associated strongly with astrocytomas which are the most
invasive form of gliomas (Palfi et al., 2004). Furthermore, NTN1 expression was associated
with poor patient prognosis. NTN1 upregulation promoted the invasiveness of glioblastoma
cells in vitro and in vivo. Consistently with our findings, another study also found that NTN1
promotes the GBM invasiveness (Shimizu et al., 2013).
To elucidate the signaling mechanisms mediating NTN1 effects we systematically screened
its binding partners using tandem affinity purification and mass spectrometry protein
identification. Out of the identified receptors, Notch pathway was the most prominent.
NTN1 physically interacted with Notch pathway components: NTN1 pulled down both
Notch2 and Jagged1 and colocalized with both Jagged1 and Notch2 on the cell surface.
However, NTN1 colocalized with Jagged1 also in cytoplasm but not with Notch2. Moreover,
NTN1 enhanced Notch activity. Both NTN1 and Notch signaling induced GBM cell invasion.
Taken together, these findings suggest that NTN1 induced cell invasion is mediated by Notch
signaling. NTN1 can bind to the complex of Notch and Jagged and activate the signaling.
Previously, Notch signaling has been associated with increased GBM invasion (Chigurupati et
al., 2010; Sivasankaran et  al., 2009; Stockhausen et  al., 2010; Zhang et  al., 2012) and
maintenance of the GSCs within GBM tumors (Chen et al., 2010; Fan et al., 2010; Hu et al.,
2011) and to the upregulation of nestin expression (Shih and Holland, 2006). In addition,
NTN1 has been linked to the up-regulation of stem cell motility and self-renewal during
developmental processes (Lee et  al., 2014; Ozmadenci et  al., 2015). Therefore, we
speculated that the NTN1 induced upregulation of Notch signaling could promote the
stemness of the glioma cells. Indeed, we observed that when NTN1 was overexpressed in
GBM cells in vitro their percentage of GSCs was increased. This suggests that NTN1 promotes
the maintenance of the GSCs within the population. Similarly to cultured cells, NTN1
colocalized with Jagged1 but not Notch2 in human GBM tissue. However, Notch2 and NTN1
did colocalize on the cell-cell contacts of neighboring cells. Similar coexpression in
neighboring cells was observed with NTN1 and CD133 and nestin. Furthermore, we observed
that in the NTN1 expressing U87MG xenografts tumors the invasive colonies or sprouts were
growing in a distinct assembly. The cells in the leading edge were positive for nestin and
Notch2  whereas  the  cells  in  the  stalk  area  of  the  sprouts  were  NTN1  positive.  Similar
structures were visible in both in vivo xenograft models and in ex vivo human GBM tissue
cultures. The structure of these sprouts was similar to those observed in NTN1 guided lung
and mammary gland morphogenesis (Dalvin et al., 2003; Liu et al., 2004).
Taken together, these finding describe a new mechanism of GBM invasiveness. NTN1 in the
stalk area of the invasive structures can activate the Notch signaling in the adjacent cells that
form  the  leading  edge  of  the  sprouts  (Fig.  5).  This  allows  the  maintenance  of  stem  like
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characteristics of the leading cells which is a great advantage because the stem-like cells are
very plastic and motile.
Figure 5. Model of the NTN1 induced invasiveness of the GBM cells. This schematic
illustration summarizes the main findings of the articles II and III. NTN1 in the stalk area of
invasive sprouts activates Notch signaling in the leading edge. Modified from (Ylivinkka et al.,
2017).
GBM tumors are heterogeneous and contain different regions. Besides the invasive front,
the GSCs are located to the hypoxic and perivascular tumor areas (Bar et al., 2010; Bar et al.,
2010; Calabrese et al., 2007; Heddleston et al., 2009). NTN1 is enriched to these same areas
and  was  located  next  to  GSCs  within  the  tumor  core.  Furthermore,  NTN1  secretion  is
upregulated under hypoxia (unpublished results). Since NTN1 and Notch can promote the
maintenance of GSCs this may give them and advantage to survive within the tumor core.
Furthermore, NTN1 induced apoptosis resistance is shown to protect the embryonic stem
cells (Ozmadenci et al., 2015). Therefore, NTN1 may have similar GSC protective mechanisms
in GBM too.
3. NTN1(II)FH overcomes the effects of full-length NTN1 and has 
therapeutic potential (II, III) 
Currently, no curative treatment exists for GBM. The only approved drug, TMZ, provides only
modest prolongation of the lifetime of the patients (Venur et  al., 2015). Therefore, the
discovery of new treatment options and enhanced targeting of the existing treatments are
vital. Infiltrative invasiveness and the stemness of the tumor cells are hallmarks of GBM and
also the main reasons for the treatment failure (Ortensi et al., 2013). Our results indicate
that NTN1 is a novel regulator of GBM invasiveness and stemness. By inhibiting NTN1
signaling both of these phenotypes could be targeted suggesting NTN1 as potential
treatment target in GBM.
Interestingly, NTN1(II)FH, a peptide consisting of the central domain of NTN1, specifically
counteracts NTN1–Notch signaling as indicated by several results: NTN1(II)FH was able to
pull down both Notch2 and Jagged1. It colocalized with Notch2 and Jagged1 at the cell
surface but not in the cytoplasm. Exogenous NTN1(II)FH also altered the morphology of
U251MG cells similarly to the Notch signaling inhibitor DAPT. The Notch2–Jagged1 signaling
complex was retained at the cell surface and less colocalization of Notch2 and clathrin was
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observed on the cell surface in the presence of NTN1(II)FH suggesting inhibition of the
signaling. Furthermore, NTN(II)FH expression inhibited the invasiveness of the GBM cells in
vitro and in vivo. This reduction in invasiveness was due to the decreased motility of GSCs.
These results suggest that NTN1 signaling inhibition could offer a powerful way to target
GBM and that NTN1(II)FH provides one possible way for targeting that.
The Notch inhibitors have been actively investigated as a possible therapeutic for GBM.
Currently two phase I/0 clinical studies have been conducted (Krop et al., 2012; Xu et al.,
2016). The first one included patients with different late stage solid tumors (Krop et al., 2012)
and the other was designed to evaluate the biological effects of the inhibitor (Xu et al., 2016).
Therefore, the patient benefit is difficult to estimate based on these studies. However, the
first study did observe that only the glioma patients responded to the treatment even though
results were not dramatic. This suggests that Notch inhibition could be effective in GBM
treatment.
Both of these clinical studies utilize GSIs which prevent the Notch activation due to the lack
of γ-secretase mediated receptor cleavage. However, it has been suggested that alternative,
γ-secretase independent ways to activate the signaling exist (Ayaz and Osborne, 2014; Baron,
2012). Therefore, it is possible that the GSI targeted treatments do not totally prevent Notch
signaling activation. In this thesis we describe a novel NTN1 induced mechanism for Notch
activation. Furthermore, according to the mass spectrometry results NTN1 can bind to
various Notch receptors. Here, we have employed Notch2 as a model receptor due to its
abundant expression in GBM cells. However, the NTN1 induced Notch activation may not be
limited to Notch2. Therefore, the described NTN1-Notch signaling inhibition with NTN1(II)FH
peptide may be of great clinical importance.
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CONCLUSIONS AND FUTURE PERSPECTIVES
In this thesis we describe two mechanism how NTNs modulate GBM pathogenity. First, we
described a mechanism of NTN4-ITGB4 that drives the proliferation of glioma cells during
the  tumor  progression  (I).  Second,  we  described  how  NTN1  promotes  glioma  cell
invasiveness and stemness via Notch signaling (II, III). Based on these findings, NTNs could
be interesting therapeutic targets. Inhibition of their signaling could inhibit both cell
proliferation and cell invasion, two major mechanisms leading to lethality of GBM. In
addition, we link NTN1 to tumor cell stemness which not only affects cell invasion but also
resistance to therapies. Furthermore, we designed a peptide that can inhibit NTN1 signaling
(II, III). This peptide has therapeutic potential: it can target both cell invasion and stemness
that are key hallmarks of gliomas.
For future studies, our results raise several questions regarding the role of NTN1 in glioma
biology. During brain injuries, NTN1 is upregulated within the SVZ (Cayre et al., 2013). There
it  increases  the  motility  of  neural  progenitors  and  promotes  angiogenesis  to  create  new
paths for neural precursor migration (Cayre et al., 2013). Similarly, the glioma cells use the
vasculature as tracks for invasion. We observed in our xenograft models that the invasive
cells migrating from NTN1 overexpressing xenografts were co-opting the surrounding
vasculature.  Therefore it is interesting to speculate that NTN1 could promote tumor
vasculature to create highways for the GSCs.
Furthermore, the cell of origin of GBM is still unclear. It has been postulated that it could be
a transformed neural stem or precursor cell raising from the SVZ (Alcantara Llaguno et al.,
2009). Since NTN1 is expressed within the SVZ and it is capable of maintaining the GSCs it
raises  the  question  whether  it  participates  to  the  initiation  of  the  GBM.  Moreover,  it  is
unclear whether the GBM tumors consist of two different cell populations: the GSCs and the
differentiated tumor cells or whether the stemness is an intrinsic property of all GBM cells.
Our results indicate that NTN1 can modulate the plasticity of the GBM cells. It altered both
U251MG and U87MG cell populations towards more stem-like phenotype suggesting that it
may play a role in the regulation of GBM heterogeneity. However, it  still  remains unclear
whether it increases the number of GSCs or whether it can reprogram the differentiated
GBM cells towards more stem-like phenotype.
Besides the mechanisms we have studied in detail in this thesis, our results implicate that
NTNs are involved in many other signaling pathways. We screened for interacting partners
of both NTN1 and NTN4 and discovered several signaling pathways and cellular functions
connected to them. For example, the identified interacting partners of NTN1 included
integrin signaling, proteolysis and endocytosis related proteins. Even though some
interacting proteins were shared between the NTN1 fragments, each of them also had
unique binding partners suggesting that NTN1 can modulate various pathways via the
different domains. Besides GBM that was used as a model in these studies, NTNs have been
linked to other cancers and other pathological conditions such as neurological diseases.
Many of the signaling pathways discovered here may be of interest within these conditions
too. Therefore, our results open many new research avenues and have implications beyond
GBM.
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